METHODS OF TREATING OSMIDROSIS

PRIORITY DATA

This application claims the benefit of United States Provisional Patent Application Serial No. 62/368,896, filed on July 29, 2016, which is incorporated herein by reference.

BACKGROUND

Sweating is an important physiological function that helps protect the body from overheating. There are millions of sweat glands distributed over the human body. Human sweat glands are primarily divided into two types: eccrine and apocrine. The majority of sweat glands are "eccrine" sweat glands, which are distributed over the entire skin surface and found in large numbers on the soles of the feet, the palms of the hands, the face, and in the armpits. Eccrine glands secrete an odorless, clear fluid that helps the body control its temperature by promoting heat loss through evaporation. However, in some cases, eccrine sweat can cause body odor. As one non-limiting example, in some circumstances, eccrine sweat can soften keratin, which can lead to bacterial degradation of the keratin and a corresponding foul smell. Another type of sweat gland is called the "apocrine" gland. Apocrine glands have a more limited distribution on the human body and are found most abundantly in the axilla, genital skin, and breasts. They produce a thick, oily fluid that produces a characteristic body odor when it comes into contact with bacteria on the surface of the skin.

While body odor can typically be controlled or masked using standard antiperspirants/deodorants, some individuals suffer from excessively foul-smelling sweat, which is considered pathologic and termed osmidrosis (also known as bromhidrosis or bromidrosis). Osmidrosis can be challenging to treat or prevent using standard antiperspirants/deodorants. As such, many patients suffering from this condition resort to alternative treatments such as microwave destruction of apocrine glands, botulinum toxin injections, and/or laser destruction of apocrine glands. In some instances, surgical removal of the apocrine glands by a radical surgical procedure is viewed as the best solution for osmidrosis. BRIEF DESCRIPTION OF THE DRAWINGS

For a fuller understanding of the nature and advantage of the present invention, reference is being made to the following detailed description of preferred embodiments and in connection with the accompanying drawings, in which: FIG. 1 is a graph illustrating siRNA-mediated inhibition of ABCClla gene expression in human HepG2 cells, in accordance with one aspect of the present disclosure.

DESCRIPTION OF EMBODIMENTS

Although the following detailed description contains many specifics for the purpose of illustration, a person of ordinary skill in the art will appreciate that many variations and alterations to the following details can be made and are considered to be included herein. Accordingly, the following embodiments are set forth without any loss of generality to, and without imposing limitations upon, any claims set forth. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

As used in this written description, the singular forms "a," "an" and "the" include express support for plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a polymer" can include a plurality of such polymers.

As used herein, "subject" refers to a mammal that can benefit from treatment with an ABCC11 inhibitor. A benefit can be obtained if the subject has a disease or condition, or is at risk of developing a disease or condition for which an ABCCl l inhibitor is a therapeutically effective treatment or preventative measure. In some aspects, such subject may be a human.

As used herein, the terms "treat," "treatment," or "treating" when used in conjunction with the administration of an ABCCl l inhibitor, such as an siRNA that targets the ABCCl l gene, including compositions and dosage forms thereof, refers to administration to subjects who are either asymptomatic or symptomatic. In other words, "treat," "treatment," or "treating" can be to reduce, ameliorate or eliminate symptoms associated with a condition present in a subject, or can be prophylactic, (i.e. to prevent or reduce the occurrence of the symptoms in a subject). Such prophylactic treatment can also be referred to as prevention of the condition. Treatment outcomes can be expected or unexpected. In one specific aspect, a treatment outcome can be a delay in occurrence or onset of a disease or conditions or the signs or symptoms thereof. In another aspect, a treatment can be reducing, ameliorating, eliminating, or otherwise providing a subject with relief from (i.e. relieving) the condition with which they are afflicted, or providing relief from signs or symptoms of the condition.

As used herein a "therapeutic agent," "drug," or "active agent" refers to an agent or compound that has a desired or intended biological effect (e.g. beneficial or positive) on a subject when administered to the subject in an appropriate or effective amount. In one aspect, an ABCCl 1 inhibitor can be a therapeutic agent.

The terms "ABCCl 1 inhibitor" or "ABCCll gene-inhibiting agent" refer to agents or compounds that are effective in inhibiting expression of the ABCCl l protein (e.g. the wild type ABCCl l protein). ABCCll is the human ATP-binding cassette (ABC) transport gene and encodes an ATP-driven efflux pump protein. ABCCl l is involved in cellular export of precursor odorants. Examples of ABCCl 1 inhibitors include but are not limited to siRNAs, miRNAs, antisense oligonucleotides, ribozymes, peptide nucleic acids, morpholinos, small molecule inhibitors, the like, or combinations thereof. Expression of the wildtype ABCCll gene could alternatively be blocked by permanent genetic manipulations including homologous recombination, CRISPR/Cas9 gene editing and the like.

As used herein, the terms "inhibit" or "inhibiting" are used to refer to a variety of inhibition techniques. For example, the terms "inhibit" or "inhibiting" can refer to pre- and/or post- transcriptional inhibition. With respect to pre-transcription inhibition,

"inhibit" or "inhibiting" can refer to preventing or reducing transcription of a gene, inducing altered transcription of a gene, and/or reducing a rate of transcription of a gene, whether permanent, semi-permanent, or transient. Thus, in some examples, "inhibit" or "inhibiting" can refer to permanent changes to the DNA, whereas in other examples no permanent change to the DNA is made. With respect to post-transcriptional inhibition,

"inhibit" or "inhibiting" can refer to preventing or reducing translation of a genetic sequence to a protein, inducing an altered translation of a genetic sequence to an altered protein (e.g. as misfolded protein, etc.), and/or reducing a rate of translation of a genetic sequence to a protein, whether permanent, semi-permanent, or transient. In some specific examples, "inhibit" or "inhibiting" can refer to pre-transcriptional inhibition. In other specific examples, "inhibit" or "inhibiting" can refer to post-transcriptional inhibition. Of course, the type of inhibition can depend on the specific type(s) of inhibitor(s) or therapeutic agent(s) employed. Thus, "inhibit" or "inhibiting" can include any decrease in expression of a gene as compared to native expression, whether pre- or post- transcriptional, partial or complete.

As used herein, the terms "formulation" and "composition" are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects the terms "formulation" and "composition" may be used to refer to a mixture of one or more active agents with a carrier or other excipients. Compositions can take nearly any physical state, including solid, liquid (i.e. solution), or gas. Furthermore, the term "dosage form" can include one or more formulation(s) or composition(s) provided in a format for administration to a subject. In one example, a composition can be a preparation that releases or otherwise administers an ABCC11 inhibitor.

The phrase "effective amount," "therapeutically effective amount," or "therapeutically effective rate(s)" of an active ingredient refer to a non-toxic, but sufficient amount or delivery rate of the active ingredient or therapeutic agent, to achieve therapeutic results in treating a disease or condition for which the drug or therapeutic is being delivered. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an "effective amount," "therapeutically effective amount," or "therapeutically effective rate(s)" may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision. The determination of a therapeutically effective amount or delivery rate is well within the ordinary skill in the art of pharmaceutical sciences and medicine. See, for example, Meiner and Tonascia,

"Clinical Trials: Design, Conduct, and Analysis," Monographs in Epidemiology and Biostatistics, Vol. 8 (1986). As used herein, "osmidrosis-reducing amount" or "odor-reducing amount" of an ABCCl l inhibitor, such as siRNA, and/or other suitable therapeutic agent refers to a sufficient amount or concentration of an ABCCl l inhibitor and/or other suitable therapeutic agent in a formulation or composition to provide an intended effect and/or achieve an intended result when administered to a subject. For example, an "osmidrosis- reducing amount" or "odor-reducing amount" of an ABCCl l inhibitor and/or other suitable therapeutic agent may be an amount sufficient to treat a particular target indication, e.g. osmidrosis or other condition for which the ABCCl l inhibitor and/or other suitable therapeutic agent can be used. In some non-limiting examples, an "osmidrosis-reducing amount" or "odor-reducing amount" can be an amount that induces inhibition of expression of the ABCCll gene in a target cell by at least a target amount. In some non-limiting examples, an "osmidrosis-reducing amount" or "odor-reducing amount" can be an amount that reduces apocrine sweat production and/or output in a subject by at least a target amount. In some non-limiting examples, an "osmidrosis- reducing amount" or "odor-reducing amount" can be an amount that reduces bacterial loading (e.g. colony forming units [CFU] per unit area) and/or activity on a skin surface by at least a target amount.

As used herein, "skin," "skin surface," "derma," "epidermis," and similar terms are used interchangeably, and refer to not only the outer skin of a subject comprising the epidermis, but also to underlying layers and to mucosal surfaces.

As used herein, a "dosing regimen" or "regimen" such as "treatment dosing regimen," or a "prophylactic dosing regimen," refers to how, when, how much, and for how long a dose of a composition can or should be administered to a subject in order to achieve an intended treatment or effect. As used herein the term "topical formulation" refers to a formulation that may be applied to skin or a mucosa. Topical formulations may, for example, be used to treat a subject by delivering an active agent or drug, such as an ABCCl l inhibitor. Topical formulations can be used for both topical and transdermal administration of substances. Examples of topical formulations include but are not limited to ointments, creams, lotions, gels, and pastes. As used herein, "topical administration" is used in its conventional sense to mean delivery of a substance, such as a therapeutically active agent, to the skin or a localized region of a subject's body. Topical administration of a drug, such as an ABCC11 inhibitor may often be advantageously applied in, for example, the treatment of osmidrosis in a subject's skin. While topical administration can be for the purpose of treating a local area or region of tissue, such as skin, topical administration can also be for the purpose of providing transdermal administration.

As used herein, "transdermal administration" refers to administration through the skin. Transdermal administration is often applied where systemic delivery of an active is desired, although it may also be useful for delivering an active to tissues underlying the skin with minimal systemic absorption.

As used herein, "carrier," and "pharmaceutically acceptable carrier" may be used interchangeably, and refer to any liquid, gel, salve, solvent, liquid, diluent, fluid ointment base, liposome, micelle, giant micelle, or the like, or any other suitable carrier that is suitable for delivery of a therapeutic agent to and/or into a target cell (e.g. an apocrine cell) and for use in contact with a subject or the subject's tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner. A number of carrier ingredients are known for use in making topical formulations, such as gelatin, polymers, fats and oils, lecithin, collagens, alcohols, water, etc.

In this application, "comprises," "comprising," "containing" and "having" and the like can have the meaning ascribed to them in U.S. Patent law and can mean "includes," "including," and the like, and are generally interpreted to be open ended terms. The terms "consisting of or "consists of are closed terms, and include only the components, structures, steps, or the like specifically listed in conjunction with such terms, as well as that which is in accordance with U.S. Patent law. "Consisting essentially of or "consists essentially of have the meaning generally ascribed to them by U.S. Patent law. In particular, such terms are generally closed terms, with the exception of allowing inclusion of additional items, materials, components, steps, or elements, that do not materially affect the basic and novel characteristics or function of the item(s) used in connection therewith. For example, trace elements present in a composition, but not affecting the compositions nature or characteristics would be permissible if present under the "consisting essentially of language, even though not expressly recited in a list of items following such terminology. When using an open ended term, like "comprising" or "including," in this written description it is understood that direct support should be afforded also to "consisting essentially of language as well as "consisting of language as if stated explicitly and vice versa.

The terms "first," "second," "third," "fourth," and the like in the description and in the claims, if any, are used for distinguishing between similar elements and not necessarily for describing a particular sequential or chronological order. It is to be understood that any terms so used are interchangeable under appropriate circumstances such that the embodiments described herein are, for example, capable of operation in sequences other than those illustrated or otherwise described herein. Similarly, if a method is described herein as comprising a series of steps, the order of such steps as presented herein is not necessarily the only order in which such steps may be performed, and certain of the stated steps may possibly be omitted and/or certain other steps not described herein may possibly be added to the method.

As used herein, the term "substantially" refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is "substantially" enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained. The use of "substantially" is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, a composition that is "substantially free of particles would either completely lack particles, or so nearly completely lack particles that the effect would be the same as if it completely lacked particles. In other words, a composition that is "substantially free of an ingredient or element may still actually contain such item as long as there is no measurable effect thereof. As used herein, the term "about" is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above" or "a little below" the endpoint. Unless otherwise stated, use of the term "about" in accordance with a specific number or numerical range should also be understood to provide support for such numerical terms or range without the term "about". For example, for the sake of convenience and brevity, a numerical range of "about 50 angstroms to about 80 angstroms" should also be understood to provide support for the range of "50 angstroms to 80 angstroms." Furthermore, it is to be understood that in this written description support for actual numerical values is provided even when the term "about" is used therewith. For example, the recitation of "about" 30 should be construed as not only providing support for values a little above and a little below 30, but also for the actual numerical value of 30 as well. As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.

Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of "about 1 to about 5" should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3, and 4 and sub-ranges such as from 1-3, from 2-4, and from 3-5, etc., as well as 1, 2, 3, 4, and 5, individually.

This same principle applies to ranges reciting only one numerical value as a minimum or a maximum. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described. Reference in this application may be made to compositions, systems, or methods that provide "improved" or "enhanced" performance. It is to be understood that unless otherwise stated, such "improvement" or "enhancement" is a measure of a benefit obtained based on a comparison to compositions, systems or methods in the prior art. Furthermore, it is to be understood that the degree of improved or enhanced performance may vary between disclosed embodiments and that no equality or consistency in the amount, degree, or realization of improvement or enhancement is to be assumed as universally applicable.

Reference throughout this specification to "an example" means that a particular feature, structure, or characteristic described in connection with the example is included in at least one embodiment. Thus, appearances of the phrases "in an example" in various places throughout this specification are not necessarily all referring to the same embodiment.

Example Embodiments

An initial overview of invention embodiments is provided below and specific embodiments are then described in further detail. This initial summary is intended to aid readers in understanding the technological concepts more quickly, but is not intended to identify key or essential features thereof, nor is it intended to limit the scope of the claimed subject matter.

The human ATP -binding cassette (ABC) transport gene (ABCC11), having the gene sequence of SEQ ID NO: 1, encodes an ATP-driven efflux pump protein that has a key role in secretion of components of cerumen (earwax) and body odor precursors from apocrine glands. Expression of wildtype ABCC11 results in wet type earwax and osmidrosis while expression of a single-nucleotide polymorphism (SNP) version (538G- A, Glyl80Arg, rsl7822931) results in the dry type earwax and no osmidrosis. There is a strong association of the ABCC11 SNP with both osmidrosis and the earwax type. For example, a dominant inheritance pattern of the GG or GA genotypes is a wet type earwax phenotype and osmidrosis, while the recessive AA genotype results in the dry type earwax phenotype and no osmidrosis. More specifically, the wildtype ABCCl l protein is N-linked glycosylated, whereas the SNP version is not. Therefore, the lack of N-linked glycosylation results in recognition of the SNP-encoded version as a misfolded protein, with resultant ubiquitination and proteosomal degradation. However, no apparent deleterious effects result from homozygous expression of the SNP version of t e ABCCll gene (the protein product that is degraded), which suggests that the wildtype version can be eliminated safely with no side effects. As such, certain S P's can lead to targeted degradation of the ABCCl l protein. In the absence of the ABCCl l protein, excretion of odor substances or odor precursors is blocked or limited and thus osmidrosis is reduced. The present disclosure describes methods and compositions for treating osmidrosis. In some examples, a method of treating osmidrosis can include inhibiting ABCCll gene expression. In some examples, inhibiting ABCCll gene expression (and therefore reducing or eliminating odor) can include administration of inhibitors such as small interfering RNAs (siRNAs), micro RNAs (miRNAs), morpholinos, antisense oligonucleotides (ASOs), peptide nucleic acids, small molecule inhibitors, the like, or combinations thereof that temporarily inhibit ABCCll expression. In some additional examples, a method of inhibiting ABCCll gene expression can include gene therapy. Gene therapy (e.g. homologous recombination, CRISPR/Cas9 gene editing, etc.) can be used to permanently alter the DNA to prevent expression of ABCCll. In some examples, a method of treating osmidrosis can include both administering an inhibitor and gene therapy.

In one embodiment, the present invention provides a method of treating a subject with osmidrosis by administering to the subject an RNA sequence that inhibits the expression of the gene encoding the ABCCl l protein (e.g. wildtype ABCCl l). As described above, it has been discovered that it is possible to suppress expression of wildtype ABCCl l without causing unwanted side effects as homozygous expression of the S P-containing gene product is degraded without any apparent adverse unwanted effects. In other words, it may be possible to remove expression of ABCCl l protein and reduce osmidrosis without any unwanted side effects. In some examples, methods of treating osmidrosis can include identifying a gene that contributes to osmidrosis and inhibiting gene expression contributing to osmidrosis in a target cell. In some additional examples, methods of treating osmidrosis can further include preparing an inhibitor to be administered to a subject having osmidrosis. In some specific examples, the gene that contributes to osmidrosis can be or include ABCC11. A variety of segments or sequences of the ABCCll gene can be targeted using a therapeutic agent to inhibit expression of the ABCCll gene, whether the inhibition is permanent, semi-permanent, or transient. For example, one or more of the gene sequences listed in Table 1 below can be targeted to inhibit ABCC11 gene expression:

Table 1

478-500 CACCGCCTTTGGGAAGAAGAAGT 37

480-502 CCGCCTTTGGGAAGAAGAAGTCT 38

482-504 GCCTTTGGGAAGAAGAAGTCTCA 39

510-532 AGGGATTGAAAAAGCTTCAGTGC 40

527-549 CAGTGCTTCTGGTGATGCTGAGG 41

536-558 TGGTGATGCTGAGGTTCCAGAGA 42

542-564 TGCTGAGGTTCCAGAGAACAAGG 43

546-568 GAGGTTCCAGAGAACAAGGTTGA 44

550-572 TTCCAGAGAACAAGGTTGATTTT 45

551-573 TCCAGAGAACAAGGTTGATTTTC 46

555-577 GAGAACAAGGTTGATTTTCGATG 47

562-584 AGGTTGATTTTCGATGCACTTCT 48

575-597 ATGCACTTCTGGGCATCTGCTTC 49

576-598 TGCACTTCTGGGCATCTGCTTCT 50

606-628 CAGTGTACTCGGGCCAATATTGA 51

616-638 GGGCCAATATTGATTATACCAAA 52

617-639 GGCCAATATTGATTATACCAAAG 53

618-640 GCCAATATTGATTATACCAAAGA 54

632-654 TACCAAAGATCCTGGAATATTCA 55

666-688 GGGGAATGCTGTCCATGGAGTGG 56

709-731 CTCTCCGAATGCGTGAAGTCTCT 57

711-733 CTCCGAATGCGTGAAGTCTCTGA 58

713-735 CCGAATGCGTGAAGTCTCTGAGT 59

717-739 ATGCGTGAAGTCTCTGAGTTTCT 60

719-741 GCGTGAAGTCTCTGAGTTTCTCC 61

732-754 GAGTTTCTCCTCCAGTTGGATCA 62

741-763 CTCCAGTTGGATCATCAACCAAC 63

742-764 TCCAGTTGGATCATCAACCAACG 64

785-807 CAGCTGTTTCCTCCTTTGCCTTT 65

786-808 AGCTGTTTCCTCCTTTGCCTTTG 66

792-814 TTCCTCCTTTGCCTTTGAGAAGC 67

801-823 TGCCTTTGAGAAGCTCATCCAAT 68

806-828 TTGAGAAGCTCATCCAATTTAAG 69

811-833 AAGCTCATCCAATTTAAGTCTGT 70

814-836 CTCATCCAATTTAAGTCTGTAAT 71

817-839 ATCCAATTTAAGTCTGTAATACA 72

861-883 CAGCTTCTTCACCGGTGATGTAA 73

862-884 AGCTTCTTCACCGGTGATGTAAA 74

872-894 CCGGTGATGTAAACTACCTGTTT 75

873-895 CGGTGATGTAAACTACCTGTTTG 76

889-911 CTGTTTGAAGGGGTGTGCTATGG 77 903-925 GTGCTATGGACCCCTAGTACTGA 78

938-960 CGCTGGTCATCTGCAGCATTTCT 79

940-962 CTGGTCATCTGCAGCATTTCTTC 80

941-963 TGGTCATCTGCAGCATTTCTTCC 81

948-970 CTGCAGCATTTCTTCCTACTTCA 82

951-973 CAGCATTTCTTCCTACTTCATTA 83

952-974 AGCATTTCTTCCTACTTCATTAT 84

960-982 TTCCTACTTCATTATTGGATACA 85

964-986 TACTTCATTATTGGATACACTGC 86

983-1005 CTGCATTTATTGCCATCTTATGC 87

993-1015 TGCCATCTTATGCTATCTCCTGG 88

1003-1025 TGCTATCTCCTGGTTTTCCCACT 89

1025-1047 TGGCGGTATTCATGACAAGAATG 90

1026-1048 GGCGGTATTCATGACAAGAATGG 91

1047-1069 GGCTGTGAAGGCTCAGCATCACA 92

1056-1078 GGCTCAGCATCACACATCTGAGG 93

1104-1126 CAGTGAAGTTCTCACTTGCATTA 94

1106-1128 GTGAAGTTCTCACTTGCATTAAG 95

1112-1134 TTCTCACTTGCATTAAGCTGATT 96

1114-1136 CTCACTTGCATTAAGCTGATTAA 97

1116-1138 CACTTGCATTAAGCTGATTAAAA 98

1119-1141 TTGCATTAAGCTGATTAAAATGT 99

1126-1148 AAGCTGATTAAAATGTACACATG 100

1127-1149 AGCTGATTAAAATGTACACATGG 101

1138-1160 ATGTACACATGGGAGAAACCATT 102

1146-1168 ATGGGAGAAACCATTTGCAGAAA 103

1147-1169 TGGGAGAAACCATTTGCAGAAAT 104

1148-1170 GGGAGAAACCATTTGCAGAAATC 105

1155-1177 ACCATTTGCAGAAATCATTGAAG 106

1163-1185 CAGAAATCATTGAAGACCTAAGA 107

1175-1197 AAGACCTAAGAAGGAAGGAAAGG 108

1178-1200 ACCTAAGAAGGAAGGAAAGGAAA 109

1182-1204 AAGAAGGAAGGAAAGGAAACTAT 110

1185-1207 AAGGAAGGAAAGGAAACTATTGG 111

1190-1212 AGGAAAGGAAACTATTGGAGAAG 112

1229-1251 GCCTGACAAGTATAACCTTGTTC 113

1233-1255 GACAAGTATAACCTTGTTCATCA 114

1236-1258 AAGTATAACCTTGTTCATCATCC 115

1280-1302 GGGTTCTCATCCACACATCCTTA 116

1289-1311 TCCACACATCCTTAAAGCTGAAA 117

1291-1313 CACACATCCTTAAAGCTGAAACT 118 1293-1315 CACATCCTTAAAGCTGAAACTCA 119

1297-1319 TCCTTAAAGCTGAAACTCACAGC 120

1316-1338 CAGCGTCAATGGCCTTCAGCATG 121

1317-1339 AGCGTCAATGGCCTTCAGCATGC 122

1332-1354 CAGCATGCTGGCCTCCTTGAATC 123

1369-1391 GTGTTCTTTGTGCCTATTGCAGT 124

1378-1400 GTGCCTATTGCAGTCAAAGGTCT 125

1380-1402 GCCTATTGCAGTCAAAGGTCTCA 126

1388-1410 CAGTCAAAGGTCTCACGAATTCC 127

1415-1437 CTGCAGTGATGAGGTTCAAGAAG 128

1416-1438 TGCAGTGATGAGGTTCAAGAAGT 129

1418-1440 CAGTGATGAGGTTCAAGAAGTTT 130

1420-1442 GTGATGAGGTTCAAGAAGTTTTT 131

1425-1447 GAGGTTCAAGAAGTTTTTCCTCC 132

1462-1484 TTCTATGTCCAGACATTACAAGA 133

1486-1508 CCCAGCAAAGCTCTGGTCTTTGA 134

1488-1510 CAGCAAAGCTCTGGTCTTTGAGG 135

1570-1592 GAGAGGAACGGGCATGCTTCTGA 136

1594-1616 GGGATGACCAGGCCTAGAGATGC 137

1649-1671 GCCCAGAGTTGCACAAGATCAAC 138

1650-1672 CCCAGAGTTGCACAAGATCAACC 139

1676-1698 TGGTGTCCAAGGGGATGATGTTA 140

1707-1729 CGGCAACACGGGGAGTGGTAAGA 141

1721-1743 GTGGTAAGAGCAGCCTGTTGTCA 142

1833-1855 CGGGAACATCAGGGAGAACATCC 143

1924-1946 CTGGAACTTCTGCCCTTTGGAGA 144

1933-1955 CTGCCCTTTGGAGACATGACAGA 145

1935-1957 GCCCTTTGGAGACATGACAGAGA 146

2089-2111 CACATTTTTGAGGAGTGCATTAA 147

2153-2175 AGCTGCAGTACTTAGAATTTTGT 148

2155-2177 CTGCAGTACTTAGAATTTTGTGG 149

2165-2187 TAGAATTTTGTGGCCAGATCATT 150

2175-2197 TGGCCAGATCATTTTGTTGGAAA 151

2176-2198 GGCCAGATCATTTTGTTGGAAAA 152

2177-2199 GCCAGATCATTTTGTTGGAAAAT 153

2179-2201 CAGATCATTTTGTTGGAAAATGG 154

2191-2213 TTGGAAAATGGGAAAATCTGTGA 155

2200-2222 GGGAAAATCTGTGAAAATGGAAC 156

2216-2238 ATGGAACTCACAGTGAGTTAATG 157

2217-2239 TGGAACTCACAGTGAGTTAATGC 158

2220-2242 AACTCACAGTGAGTTAATGCAGA 159 2222-2244 CTCACAGTGAGTTAATGCAGAAA 160

2224-2246 CACAGTGAGTTAATGCAGAAAAA 161

2226-2248 CAGTGAGTTAATGCAGAAAAAGG 162

2236-2258 ATGCAGAAAAAGGGGAAATATGC 163

2246-2268 AGGGGAAATATGCCCAACTTATC 164

2247-2269 GGGGAAATATGCCCAACTTATCC 165

2256-2278 TGCCCAACTTATCCAGAAGATGC 166

2266-2288 ATCCAGAAGATGCACAAGGAAGC 167

2305-2327 CAGGACACAGCAAAGATAGCAGA 168

2322-2344 AGCAGAGAAGCCAAAGGTAGAAA 169

2326-2348 GAGAAGCCAAAGGTAGAAAGTCA 170

2371-2393 GAGTCTCTCAACGGAAATGCTGT 171

2373-2395 GTCTCTCAACGGAAATGCTGTGC 172

2425-2447 ATGGAAGAAGGCTCCTTGAGTTG 173

2426-2448 TGGAAGAAGGCTCCTTGAGTTGG 174

2480-2502 GAGGTTACATGGTCTCTTGCATA 175

2481-2503 AGGTTACATGGTCTCTTGCATAA 176

2485-2507 TACATGGTCTCTTGCATAATTTT 177

2489-2511 TGGTCTCTTGCATAATTTTCTTC 178

2493-2515 CTCTTGCATAATTTTCTTCTTCG 179

2496-2518 TTGCATAATTTTCTTCTTCGTGG 180

2516-2538 TGGTGCTGATCGTCTTCTTAACG 181

2519-2541 TGCTGATCGTCTTCTTAACGATC 182

2525-2547 TCGTCTTCTTAACGATCTTCAGC 183

2629-2651 GGCAACATTGCAGACAATCCTCA 184

2632-2654 AACATTGCAGACAATCCTCAACT 185

2636-2658 TTGCAGACAATCCTCAACTGTCC 186

2646-2668 TCCTCAACTGTCCTTCTACCAGC 187

2720-2742 CAGGGATTTTCACCAAGGTCACG 188

2759-2781 CCCTGCACAACAAGCTCTTTAAC 189

2762-2784 TGCACAACAAGCTCTTTAACAAG 190

2767-2789 AACAAGCTCTTTAACAAGGTTTT 191

2795-2817 GCCCCATGAGTTTCTTTGACACC 192

2806-2828 TTCTTTGACACCATCCCAATAGG 193

2819-2841 TCCCAATAGGCCGGCTTTTGAAC 194

2820-2842 CCCAATAGGCCGGCTTTTGAACT 195

2870-2892 ACCAGCTCTTGCCCATCTTTTCA 196

2872-2894 CAGCTCTTGCCCATCTTTTCAGA 197

2950-2972 CTGTCTCCATATATCCTGTTAAT 198

2952-2974 GTCTCCATATATCCTGTTAATGG 199

2963-2985 TCCTGTTAATGGGAGCCATAATC 200 2973-2995 GGGAGCCATAATCATGGTTATTT 201

2975-2997 GAGCCATAATCATGGTTATTTGC 202

2983-3005 ATCATGGTTATTTGCTTCATTTA 203

2986-3008 ATGGTTATTTGCTTCATTTATTA 204

2987-3009 TGGTTATTTGCTTCATTTATTAT 205

2994-3016 TTGCTTCATTTATTATATGATGT 206

3037-3059 TTCAAGAGACTGGAGAACTATAG 207

3052-3074 AACTATAGCCGGTCTCCTTTATT 208

3066-3088 TCCTTTATTCTCCCACATCCTCA 209

3075-3097 CTCCCACATCCTCAATTCTCTGC 210

3108-3130 CTCCATCCATGTCTATGGAAAAA 211

3109-3131 TCCATCCATGTCTATGGAAAAAC 212

3112-3134 ATCCATGTCTATGGAAAAACTGA 213

3122-3144 ATGGAAAAACTGAAGACTTCATC 214

3123-3145 TGGAAAAACTGAAGACTTCATCA 215

3134-3156 AAGACTTCATCAGCCAGTTTAAG 216

3148-3170 CAGTTTAAGAGGCTGACTGATGC 217

3158-3180 GGCTGACTGATGCGCAGAATAAC 218

3182-3204 ACCTGCTGTTGTTTCTATCTTCC 219

3185-3207 TGCTGTTGTTTCTATCTTCCACA 220

3187-3209 CTGTTGTTTCTATCTTCCACACG 221

3216-3238 GGCATTGAGGCTGGAGATCATGA 222

3263-3285 CCCTGTTCGTGGCTTTTGGCATT 223

3269-3291 TCGTGGCTTTTGGCATTTCCTCC 224

3293-3315 CCCCCTACTCCTTTAAAGTCATG 225

3294-3316 CCCCTACTCCTTTAAAGTCATGG 226

3374-3396 TGGAGACAGAGGCACAGTTCACG 227

3384-3406 GGCACAGTTCACGGCTGTAGAGA 228

3386-3408 CACAGTTCACGGCTGTAGAGAGG 229

3396-3418 GGCTGTAGAGAGGATACTGCAGT 230

3405-3427 GAGGATACTGCAGTACATGAAGA 231

3410-3432 TACTGCAGTACATGAAGATGTGT 232

3412-3434 CTGCAGTACATGAAGATGTGTGT 234

3449-3471 TACACATGGAAGGCACAAGTTGT 235

3451-3473 CACATGGAAGGCACAAGTTGTCC 236

3483-3505 GCCACAGCATGGGGAAATCATAT 237

3492-3514 TGGGGAAATCATATTTCAGGATT 238

3493-3515 GGGGAAATCATATTTCAGGATTA 239

3494-3516 GGGAAATCATATTTCAGGATTAT 240

3506-3528 TTCAGGATTATCACATGAAATAC 241

3509-3531 AGGATTATCACATGAAATACAGA 242 3515-3537 ATCACATGAAATACAGAGACAAC 243

3520-3542 ATGAAATACAGAGACAACACACC 244

3676-3698 CTCATTGACGGCGTGGACATTTG 245

3713-3735 AGGACTTGCGGTCCAAGCTCTCA 246

3720-3742 GCGGTCCAAGCTCTCAGTGATCC 247

3730-3752 CTCTCAGTGATCCCTCAAGATCC 248

3757-3779 CTGCTCTCAGGAACCATCAGATT 249

3765-3787 AGGAACCATCAGATTCAACCTAG 250

3768-3790 AACCATCAGATTCAACCTAGATC 251

3769-3791 ACCATCAGATTCAACCTAGATCC 252

3789-3811 TCCCTTTGACCGTCACACTGACC 253

3825-3847 TGCCTTGGAGAGGACATTCCTGA 254

3842-3864 TCCTGACCAAGGCCATCTCAAAG 255

3858-3880 CTCAAAGTTCCCCAAAAAGCTGC 256

3865-3887 TTCCCCAAAAAGCTGCATACAGA 257

3867-3889 CCCCAAAAAGCTGCATACAGATG 258

3868-3890 CCCAAAAAGCTGCATACAGATGT 259

3890-3912 TGGTGGAAAACGGTGGAAACTTC 260

3893-3915 TGGAAAACGGTGGAAACTTCTCT 261

3948-3970 GGCTGTGCTTCGCAACTCCAAGA 262

3953-3975 TGCTTCGCAACTCCAAGATCATC 263

3957-3979 TCGCAACTCCAAGATCATCCTTA 264

3958-3980 CGCAACTCCAAGATCATCCTTAT 265

3963-3985 CTCCAAGATCATCCTTATCGATG 266

3964-3986 TCCAAGATCATCCTTATCGATGA 267

3967-3989 AAGATCATCCTTATCGATGAAGC 268

3996-4018 CTCCATTGACATGGAGACAGACA 269

4086-4108 CACCACTGTGCTGAACTGTGACC 270

4112-4134 TCCTGGTTATGGGCAATGGGAAG 271

4122-4144 GGGCAATGGGAAGGTGGTAGAAT 272

4123-4145 GGCAATGGGAAGGTGGTAGAATT 273

4128-4150 TGGGAAGGTGGTAGAATTTGATC 274

4205-4227 CAGCCACTTCTTCACTGAGATAA 275

4206-4228 AGCCACTTCTTCACTGAGATAAG 276

4207-4229 GCCACTTCTTCACTGAGATAAGG 277

4212-4234 TTCTTCACTGAGATAAGGAGATG 278

4215-4237 TTCACTGAGATAAGGAGATGTGG 279

4226-4248 AAGGAGATGTGGAGACTTCATGG 280

4229-4251 GAGATGTGGAGACTTCATGGAGG 281

4284-4306 CAGCTTCGAGGCCCACAGTCTGC 282

4295-4317 CCCACAGTCTGCGACCTTCTTGT 283 4305-4327 GCGACCTTCTTGTTTGGAGATGA 284

4307-4329 GACCTTCTTGTTTGGAGATGAGA 285

4318-4340 TTGGAGATGAGAACTTCTCCTGG 286

4334-4356 CTCCTGGAAGCAGGGGTAAATGT 287

4337-4359 CTGGAAGCAGGGGTAAATGTAGG 289

4364-4386 GTGGGGATTGCTGGATGGAAACC 290

4374-4396 CTGGATGGAAACCCTGGAATAGG 291

4379-4401 TGGAAACCCTGGAATAGGCTACT 292

4384-4406 ACCCTGGAATAGGCTACTTGATG 293

4385-4407 CCCTGGAATAGGCTACTTGATGG 294

4415-4437 GACCTTAGAACCCCAGAACCATC 295

4416-4438 ACCTTAGAACCCCAGAACCATCT 296

4424-4446 ACCCCAGAACCATCTAAGACATG 297

4425-4447 CCCCAGAACCATCTAAGACATGG 298

4431-4453 AACCATCTAAGACATGGGATTCA 299

4435-4457 ATCTAAGACATGGGATTCAGTGA 300

4441-4463 GACATGGGATTCAGTGATCATGT 301

4446-4468 GGGATTCAGTGATCATGTGGTTC 302

4454-4476 GTGATCATGTGGTTCTCCTTTTA 303

4457-4479 ATCATGTGGTTCTCCTTTTAACT 304

4460-4482 ATGTGGTTCTCCTTTTAACTTAC 305

4463-4485 TGGTTCTCCTTTTAACTTACATG 306

4469-4491 TCCTTTTAACTTACATGCTGAAT 307

4476-4498 AACTTACATGCTGAATAATTTTA 308

4480-4502 TACATGCTGAATAATTTTATAAT 309

4483-4505 ATGCTGAATAATTTTATAATAAG 310

4484-4506 TGCTGAATAATTTTATAATAAGG 311

4503-4525 AAGGTAAAAGCTTATAGTTTTCT 312

4510-4532 AAGCTTATAGTTTTCTGATCTGT 313

4524-4546 CTGATCTGTGTTAGAAGTGTTGC 314

4529-4551 CTGTGTTAGAAGTGTTGCAAATG 315

4535-4557 TAGAAGTGTTGCAAATGCTGTAC 316

4540-4562 GTGTTGCAAATGCTGTACTGACT 317

4543-4565 TTGCAAATGCTGTACTGACTTTG 318

4544-4566 TGCAAATGCTGTACTGACTTTGT 319

4549-4571 ATGCTGTACTGACTTTGTAAAAT 320

4550-4572 TGCTGTACTGACTTTGTAAAATA 321

4552-4574 CTGTACTGACTTTGTAAAATATA 322

4555-4577 TACTGACTTTGTAAAATATAAAA 323

4557-4579 CTGACTTTGTAAAATATAAAACT 324

4559-4581 GACTTTGTAAAATATAAAACTAA 325 As described above, in some examples, one or more of SEQ ID NOs: 2-325, or portions thereof, can be targeted to inhibit expression of the ABCCll gene. In yet other examples, two or more of SEQ ID NOs: 2-325, or portions thereof, can be targeted to inhibit expression of the ABCCll gene. In still other examples, three or more, four or more, five or more, or ten or more of SEQ ID NOs: 2-325, or portions thereof, can be targeted to inhibit expression of the ABCCll gene. In some examples, each of SEQ ID NOs: 2-325, or portions thereof, can be targeted to inhibit expression of the ABCCll gene. In some examples, SEQ ID NO: 2, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 3, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 4, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 5, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 6, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 7, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 8, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 9, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 10, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 11, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 12, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 13, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 14, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 15, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 16, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 17, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 18, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 19, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 20, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 21, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 22, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 23, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 24, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 25, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 26, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 27, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 28, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 29, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 30, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 31, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 32, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 33, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 34, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 35, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 36, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 37, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 38, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 39, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 40, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 41, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 42, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 43, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 44, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 45, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 46, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 47, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 48, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 49, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 50, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 51, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 52, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 53, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 54, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 55, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 56, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 57, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 58, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 59, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 60, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 61, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 62, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 63, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 64, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 65, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 66, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 67, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 68, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 69, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 70, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 71, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 72, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 73, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 74, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 75, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 76, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 77, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 78, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 79, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 80, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 81, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 82, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 83, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 84, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 85, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 86, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 87, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 88, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 89, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 90, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 91, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 92, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 93, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 94, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 95, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 96, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 97, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 98, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 99, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 100, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 101, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 102, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 103, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 104, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 105, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 106, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 107, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 108, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 109, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 110, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 111, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 112, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 113, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 114, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 115, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 116, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 117, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 118, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 119, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 120, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 121, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 122, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 123, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 124, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 125, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 126, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 127, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 128, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 129, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 130, or a portion thereof, can be targeted. In some examples, SEQ ID NO:

131, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 132, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 133, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 134, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 135, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 136, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 137, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 138, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 139, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 140, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 141, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 142, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 143, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 144, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 145, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 146, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 147, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 148, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 149, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 150, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 151, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 152, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 153, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 154, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 155, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 156, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 157, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 158, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 159, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 160, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 161, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 162, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 163, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 164, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 165, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 166, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 167, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 168, or a portion thereof, can be targeted. In some examples,

SEQ ID NO: 169, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 170, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 171, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 172, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 173, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 174, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 175, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 176, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 177, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 178, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 179, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 180, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 181, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 182, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 183, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 184, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 185, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 186, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 187, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 188, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 189, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 190, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 191, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 192, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 193, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 194, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 195, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 196, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 197, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 198, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 199, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 200, or a portion thereof, can be targeted. In some examples, SEQ ID NO:

201, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 202, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 203, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 204, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 205, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 206, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 207, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 208, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 209, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 210, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 211, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 212, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 213, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 214, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 215, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 216, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 217, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 218, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 219, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 220, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 221, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 222, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 223, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 224, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 225, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 226, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 227, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 228, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 229, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 230, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 231, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 232, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 233, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 234, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 235, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 236, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 237, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 238, or a portion thereof, can be targeted. In some examples,

SEQ ID NO: 239, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 240, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 241, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 242, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 243, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 244, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 245, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 246, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 247, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 248, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 249, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 250, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 251, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 252, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 253, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 254, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 255, or a portion thereof, can be targeted. In some examples, SEQ ID NO:

256, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 257, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 258, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 259, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 260, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 261, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 262, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 263, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 264, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 265, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 266, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 267, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 268, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 269, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 270, or a portion thereof, can be targeted. In some examples, SEQ ID NO:

271, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 272, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 273, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 274, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 275, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 276, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 277, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 278, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 279, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 280, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 281, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 282, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 283, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 284, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 285, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 286, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 287, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 288, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 289, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 290, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 291, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 292, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 293, or a portion thereof, can be targeted. In some examples,

SEQ ID NO: 294, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 295, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 296, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 297, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 298, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 299, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 300, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 301, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 302, or a portion thereof, can be targeted. In some examples, SEQ ID NO:

303, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 304, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 305, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 306, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 307, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 308, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 309, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 310, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 311, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 312, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 313, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 314, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 315, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 316, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 317, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 318, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 319, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 320, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 321, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 322, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 323, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 324, or a portion thereof, can be targeted. In some examples, SEQ ID NO: 325, or a portion thereof, can be targeted.

As described above, ABCCl l inhibitors are a potential class of pharmaceutically active agents that can be useful in treating a variety of conditions or symptoms. An example of such a symptom is osmidrosis. ABCCl l inhibitors can be administered in a variety of ways, including, but not limited to, oral, topical, intravenous, intrathecal, intradermal, and transdermal administration. Therefore, ABCCl l inhibitors can be used to treat osmidrosis symptoms both systemically and in targeted regions or areas of a subject's body. For example, a subject may experience osmidrosis due to expression of the wildtype ABCC11 gene. Accordingly, an ABCC11 inhibitor can be administered as a first line of treatment to reduce odor. When odor is manifested in the skin, it may be desirable to apply treatment directly to the situs afflicted with these symptoms. For example, the situs can include the axillary region (e.g. armpits), the pectoral region (e.g. chest/breasts), or the genital region.

Some non-limiting examples of inhibitors or therapeutic agents can be those used for gene therapy. For example, in some cases, CRISPR-Cas9 systems can be employed. For example, by delivering a Cas9 nuclease complexed with a synthetic guide RNA into a cell, the cell's genome can be cut as a desired location, allowing existing genes to be removed and/or altered genes to be added. Thus, in some examples, a CRISPR-Cas9 system can be administered to an individual having a GG or GA genotype to remove this particular version of the ABCCll gene and replace it with a version that includes the SNP version (538G-^A, Glyl80Arg, rsl7822931) of the gene. In other examples, a therapeutic nucleotide including the rs 17822931 SNP can be introduced into a target cell via a viral vector or via non-viral methods. Where viral vectors are used, any suitable viral vector can be employed. Non-limiting examples can include adenovirus, adeno- associated virus, retrovirus, lentivirus, herpes simplex, vaccinia, the like, or combinations thereof. Additionally, any suitable non-viral method can additionally or alternatively be employed. Non-limiting examples of non-viral methods can include electroporation, iontophoresis sonoporation, magnetofection, use of carriers (e.g. polymeric, dendritic, liposomic, etc.), gene gun, injection (including by arrays of microneedles) of naked or modified nucleotides, the like, or combinations thereof.

Other non-limiting examples of inhibitors or therapeutic agents can include siRNAs, miRNAs, morpholinos, ASOs, peptide nucleic acids, small molecule inhibitors, analogues thereof, derivatives thereof, the like, or combinations thereof. Generally, any therapeutic agent that can inhibit the expression of the ABCCll gene or facilitate targeted degradation of the ABCCl l protein can be used. In some specific examples, the inhibitor can include an siRNA. In some additional examples, the inhibitor can include an miRNA. In yet additional examples, the inhibitor can include a morpholino. In still additional examples, the inhibitor can include an ASO. In some examples, the inhibitor can include a peptide nucleic acid. In some further examples, the inhibitor can include a small molecule inhibitor.

In some examples, the inhibitor can include an RNA sequence, such as an siRNA, miRNA, morpholino, ASO, analogues thereof, derivatives thereof, the like, or a combination thereof. In such examples, the RNA sequence can be administered to a target cell of a subject having osmidrosis. Target cells can include any suitable apocrine target cell. In some examples, the target cells can be or include any suitable ductal epithelial apocrine cell. In some examples, target cells can include axillary apocrine cells, pectoral apocrine cells, genital apocrine cells, or a combination thereof. The prepared inhibitory sequences can vary in length but generally are from about 15 to 31 bases in length. In some examples, these prepared sequences can be siRNAs. A variety of siRNAs can be used, such as one or more (i.e. any suitable combination) of those listed in Table 2 below:

Table 2

UGUCGAUGCCACGAUUCACGA 348

SEQ ID NO: 13

GUGAAUCGUGGCAUCGACAUA 349

UAUGUCGAUGCCACGAUUCAC 350

SEQ ID NO: 14

GAAUCGUGGCAUCGACAUAGG 351

UCCUGAAACCAUGUCAUCGCC 352

SEQ ID NO: 15

CGAUGACAUGGUUUCAGGACU 353

UAAGUCCUGAAACCAUGUCAU 354

SEQ ID NO: 16

GACAUGGUUUCAGGACUUAUU 355

AAUAAGUCCUGAAACCAUGUC 356

SEQ ID NO: 17

CAUGGUUUCAGGACUUAUUUA 357

AUAAAUAAGUCCUGAAACCAU 358

SEQ ID NO: 18

GGUUUCAGGACUUAUUUAUAA 359

UAUAAAUAAGUCCUGAAACCA 360

SEQ ID NO: 19

GUUUCAGGACUUAUUUAUAAA 361

AGGUUUUAUAAAUAAGUCCUG 362

SEQ ID NO: 20

GGACUUAUUUAUAAAACCUAU 363

UAGGUUUUAUAAAUAAGUCCU 364

SEQ ID NO: 21

GACUUAUUUAUAAAACCUAUA 365

UAUAGGUUUUAUAAAUAAGUC 366

SEQ ID NO: 22

CUUAUUUAUAAAACCUAUACU 367

UUUCUCUCUUGCUGACUCCAG 368

SEQ ID NO: 23

GGAGUCAGCAAGAGAGAAAUC 369

UCUCAAGGCAGCAUCAUACUU 370

SEQ ID NO: 24

GUAUGAUGCUGCCUUGAGAAC 371

AGAACAGGCCAGCAUUGUCCA 372

SEQ ID NO: 25

GACAAUGCUGGCCUGUUCUCC 373

AAGCUUUGGAUCAUGAGCGGG 374

SEQ ID NO: 26

CGCUCAUGAUCCAAAGCUUAC 375

UAAGCUUUGGAUCAUGAGCGG 376

SEQ ID NO: 27

GCUCAUGAUCCAAAGCUUACG 377

UCUAAGCGACUCCGUAAGCUU 378

SEQ ID NO: 28

GCUUACGGAGUCGCUUAGAUG 379

AUCUAAGCGACUCCGUAAGCU 380

SEQ ID NO: 29

CUUACGGAGUCGCUUAGAUGA 381

AUGGUGUUCUCAUCUAAGCGA 382

SEQ ID NO: 30

GCUUAGAUGAGAACACCAUCC 383

UUUGUCUGAGGCAUCAUGGAC 384

SEQ ID NO: 31

CCAUGAUGCCUCAGACAAAAA 385

UUUUGUCUGAGGCAUCAUGGA 386

SEQ ID NO: 32

CAUGAUGCCUCAGACAAAAAU 387

UGGACAUUUUUGUCUGAGGCA 388

SEQ ID NO: 33

CCUCAGACAAAAAUGUCCAAA 389

UUGGACAUUUUUGUCUGAGGC 390

SEQ ID NO: 34

CUCAGACAAAAAUGUCCAAAG 391

AAGCCUUUGGACAUUUUUGUC 392

SEQ ID NO: 35

CAAAAAUGUCCAAAGGCUUCA 393

UUCCCAAAGGCGGUGAAGCCU 394

SEQ ID NO: 36

GCUUCACCGCCUUUGGGAAGA 395 UUCUUCUUCCCAAAGGCGGUG 396

SEQ ID NO: 37

CCGCCUUUGGGAAGAAGAAGU 397

ACUUCUUCUUCCCAAAGGCGG 398

SEQ ID NO: 38

GCCUUUGGGAAGAAGAAGUCU 399

AGACUUCUUCUUCCCAAAGGC 400

SEQ ID NO: 39

CUUUGGGAAGAAGAAGUCUCA 401

ACUGAAGCUUUUUCAAUCCCU 402

SEQ ID NO: 40

GGAUUGAAAAAGCUUCAGUGC 403

UCAGCAUCACCAGAAGCACUG 404

SEQ ID NO: 41

GUGCUUCUGGUGAUGCUGAGG 405

UCUGGAACCUCAGCAUCACCA 406

SEQ ID NO: 42

GUGAUGCUGAGGUUCCAGAGA 407

UUGUUCUCUGGAACCUCAGCA 408

SEQ ID NO: 43

CUGAGGUUCCAGAGAACAAGG 409

AACCUUGUUCUCUGGAACCUC 410

SEQ ID NO: 44

GGUUCCAGAGAACAAGGUUGA 411

AAUCAACCUUGUUCUCUGGAA 412

SEQ ID NO: 45

CCAGAGAACAAGGUUGAUUUU 413

AAAUCAACCUUGUUCUCUGGA 414

SEQ ID NO: 46

CAGAGAACAAGGUUGAUUUUC 415

UCGAAAAUCAACCUUGUUCUC 416

SEQ ID NO: 47

GAACAAGGUUGAUUUUCGAUG 417

AAGUGCAUCGAAAAUCAACCU 418

SEQ ID NO: 48

GUUGAUUUUCGAUGCACUUCU 419

AGCAGAUGCCCAGAAGUGCAU 420

SEQ ID NO: 49

GCACUUCUGGGCAUCUGCUUC 421

AAGCAGAUGCCCAGAAGUGCA 422

SEQ ID NO: 50

CACUUCUGGGCAUCUGCUUCU 423

AAUAUUGGCCCGAGUACACUG 424

SEQ ID NO: 51

GUGUACUCGGGCCAAUAUUGA 425

UGGUAUAAUCAAUAUUGGCCC 426

SEQ ID NO: 52

GCCAAUAUUGAUUAUACCAAA 427

UUGGUAUAAUCAAUAUUGGCC 428

SEQ ID NO: 53

CCAAUAUUGAUUAUACCAAAG 429

UUUGGUAUAAUCAAUAUUGGC 430

SEQ ID NO: 54

CAAUAUUGAUUAUACCAAAGA 431

AAUAUUCCAGGAUCUUUGGUA 432

SEQ ID NO: 55

CCAAAGAUCCUGGAAUAUUCA 433

ACUCCAUGGACAGCAUUCCCC 434

SEQ ID NO: 56

GGAAUGCUGUCCAUGGAGUGG 435

AGACUUCACGCAUUCGGAGAG 436

SEQ ID NO: 57

CUCCGAAUGCGUGAAGUCUCU 437

AGAGACUUCACGCAUUCGGAG 438

SEQ ID NO: 58

CCGAAUGCGUGAAGUCUCUGA 439

UCAGAGACUUCACGCAUUCGG 440

SEQ ID NO: 59

GAAUGCGUGAAGUCUCUGAGU 441

AAACUCAGAGACUUCACGCAU 442

SEQ ID NO: 60

GCGUGAAGUCUCUGAGUUUCU 443 AGAAACUCAGAGACUUCACGC 444

SEQ ID NO: 61

GUGAAGUCUCUGAGUUUCUCC 445

AUCCAACUGGAGGAGAAACUC 446

SEQ ID NO: 62

GUUUCUCCUCCAGUUGGAUCA 447

UGGUUGAUGAUCCAACUGGAG 448

SEQ ID NO: 63

CCAGUUGGAUCAUCAACCAAC 449

UUGGUUGAUGAUCCAACUGGA 450

SEQ ID NO: 64

CAGUUGGAUCAUCAACCAACG 451

AGGCAAAGGAGGAAACAGCUG 452

SEQ ID NO: 65

GCUGUUUCCUCCUUUGCCUUU 453

AAGGCAAAGGAGGAAACAGCU 454

SEQ ID NO: 66

CUGUUUCCUCCUUUGCCUUUG 455

UUCUCAAAGGCAAAGGAGGAA 456

SEQ ID NO: 67

CCUCCUUUGCCUUUGAGAAGC 457

UGGAUGAGCUUCUCAAAGGCA 458

SEQ ID NO: 68

CCUUUGAGAAGCUCAUCCAAU 459

UAAAUUGGAUGAGCUUCUCAA 460

SEQ ID NO: 69

GAGAAGCUCAUCCAAUUUAAG 461

AGACUUAAAUUGGAUGAGCUU 462

SEQ ID NO: 70

GCUCAUCCAAUUUAAGUCUGU 463

UACAGACUUAAAUUGGAUGAG 464

SEQ ID NO: 71

CAUCCAAUUUAAGUCUGUAAU 465

UAUUACAGACUUAAAUUGGAU 466

SEQ ID NO: 72

CCAAUUUAAGUCUGUAAUACA 467

ACAUCACCGGUGAAGAAGCUG 468

SEQ ID NO: 73

GCUUCUUCACCGGUGAUGUAA 469

UACAUCACCGGUGAAGAAGCU 470

SEQ ID NO: 74

CUUCUUCACCGGUGAUGUAAA 471

ACAGGUAGUUUACAUCACCGG 472

SEQ ID NO: 75

GGUGAUGUAAACUACCUGUUU 473

AACAGGUAGUUUACAUCACCG 474

SEQ ID NO: 76

GUGAUGUAAACUACCUGUUUG 475

AUAGCACACCCCUUCAAACAG 476

SEQ ID NO: 77

GUUUGAAGGGGUGUGCUAUGG 477

AGUACUAGGGGUCCAUAGCAC 478

SEQ ID NO: 78

GCUAUGGACCCCUAGUACUGA 479

AAAUGCUGCAGAUGACCAGCG 480

SEQ ID NO: 79

CUGGUCAUCUGCAGCAUUUCU 481

AGAAAUGCUGCAGAUGACCAG 482

SEQ ID NO: 80

GGUCAUCUGCAGCAUUUCUUC 483

AAGAAAUGCUGCAGAUGACCA 484

SEQ ID NO: 81

GUCAUCUGCAGCAUUUCUUCC 485

AAGUAGGAAGAAAUGCUGCAG 486

SEQ ID NO: 82

GCAGCAUUUCUUCCUACUUCA 487

AUGAAGUAGGAAGAAAUGCUG 488

SEQ ID NO: 83

GCAUUUCUUCCUACUUCAUUA 489

AAUGAAGUAGGAAGAAAUGCU 490

SEQ ID NO: 84

CAUUUCUUCCUACUUCAUUAU 491 UAUCCAAUAAUGAAGUAGGAA 492

SEQ ID NO: 85

CCUACUUCAUUAUUGGAUACA 493

AGUGUAUCCAAUAAUGAAGUA 494

SEQ ID NO: 86

CUUCAUUAUUGGAUACACUGC 495

AUAAGAUGGCAAUAAAUGCAG 496

SEQ ID NO: 87

GCAUUUAUUGCCAUCUUAUGC 497

AGGAGAUAGCAUAAGAUGGCA 498

SEQ ID NO: 88

CCAUCUUAUGCUAUCUCCUGG 499

UGGGAAAACCAGGAGAUAGCA 500

SEQ ID NO: 89

CUAUCUCCUGGUUUUCCCACU 501

UUCUUGUCAUGAAUACCGCCA 502

SEQ ID NO: 90

GCGGUAUUCAUGACAAGAAUG 503

AUUCUUGUCAUGAAUACCGCC 504

SEQ ID NO: 91

CGGUAUUCAUGACAAGAAUGG 505

UGAUGCUGAGCCUUCACAGCC 506

SEQ ID NO: 92

CUGUGAAGGCUCAGCAUCACA 507

UCAGAUGUGUGAUGCUGAGCC 508

SEQ ID NO: 93

CUCAGCAUCACACAUCUGAGG 509

AUGCAAGUGAGAACUUCACUG 510

SEQ ID NO: 94

GUGAAGUUCUCACUUGCAUUA 511

UAAUGCAAGUGAGAACUUCAC 512

SEQ ID NO: 95

GAAGUUCUCACUUGCAUUAAG 513

UCAGCUUAAUGCAAGUGAGAA 514

SEQ ID NO: 96

CUCACUUGCAUUAAGCUGAUU 515

AAUCAGCUUAAUGCAAGUGAG 516

SEQ ID NO: 97

CACUUGCAUUAAGCUGAUUAA 517

UUAAUCAGCUUAAUGCAAGUG 518

SEQ ID NO: 98

CUUGCAUUAAGCUGAUUAAAA 519

AUUUUAAUCAGCUUAAUGCAA 520

SEQ ID NO: 99

GCAUUAAGCUGAUUAAAAUGU 521

UGUGUACAUUUUAAUCAGCUU 522

SEQ ID NO: 100

GCUGAUUAAAAUGUACACAUG 523

AUGUGUACAUUUUAAUCAGCU 524

SEQ ID NO: 101

CUGAUUAAAAUGUACACAUGG 525

UGGUUUCUCCCAUGUGUACAU 526

SEQ ID NO: 102

GUACACAUGGGAGAAACCAUU 527

UCUGCAAAUGGUUUCUCCCAU 528

SEQ ID NO: 103

GGGAGAAACCAUUUGCAGAAA 529

UUCUGCAAAUGGUUUCUCCCA 530

SEQ ID NO: 104

GGAGAAACCAUUUGCAGAAAU 531

UUUCUGCAAAUGGUUUCUCCC 532

SEQ ID NO: 105

GAGAAACCAUUUGCAGAAAUC 533

UCAAUGAUUUCUGCAAAUGGU 534

SEQ ID NO: 106

CAUUUGCAGAAAUCAUUGAAG 535

UUAGGUCUUCAAUGAUUUCUG 536

SEQ ID NO: 107

GAAAUCAUUGAAGACCUAAGA 537

UUUCCUUCCUUCUUAGGUCUU 538

SEQ ID NO: 108

GACCUAAGAAGGAAGGAAAGG 539 UCCUUUCCUUCCUUCUUAGGU 540

SEQ ID NO: 109

CUAAGAAGGAAGGAAAGGAAA 541

AGUUUCCUUUCCUUCCUUCUU 542

SEQ ID NO: 110

GAAGGAAGGAAAGGAAACUAU 543

AAUAGUUUCCUUUCCUUCCUU 544

SEQ ID NO: 111

GGAAGGAAAGGAAACUAUUGG 545

UCUCCAAUAGUUUCCUUUCCU 546

SEQ ID NO: 112

GAAAGGAAACUAUUGGAGAAG 547

ACAAGGUUAUACUUGUCAGGC 548

SEQ ID NO: 113

CUGACAAGUAUAACCUUGUUC 549

AUGAACAAGGUUAUACUUGUC 550

SEQ ID NO: 114

CAAGUAUAACCUUGUUCAUCA 551

AUGAUGAACAAGGUUAUACUU 552

SEQ ID NO: 115

GUAUAACCUUGUUCAUCAUCC 553

AGGAUGUGUGGAUGAGAACCC 554

SEQ ID NO: 116

GUUCUCAUCCACACAUCCUUA 555

UCAGCUUUAAGGAUGUGUGGA 556

SEQ ID NO: 117

CACACAUCCUUAAAGCUGAAA 557

UUUCAGCUUUAAGGAUGUGUG 558

SEQ ID NO: 118

CACAUCCUUAAAGCUGAAACU 559

AGUUUCAGCUUUAAGGAUGUG 560

SEQ ID NO: 119

CAUCCUUAAAGCUGAAACUCA 561

UGUGAGUUUCAGCUUUAAGGA 562

SEQ ID NO: 120

CUUAAAGCUGAAACUCACAGC 563

UGCUGAAGGCCAUUGACGCUG 564

SEQ ID NO: 121

GCGUCAAUGGCCUUCAGCAUG 565

AUGCUGAAGGCCAUUGACGCU 566

SEQ ID NO: 122

CGUCAAUGGCCUUCAGCAUGC 567

UUCAAGGAGGCCAGCAUGCUG 568

SEQ ID NO: 123

GCAUGCUGGCCUCCUUGAAUC 569

UGCAAUAGGCACAAAGAACAC 570

SEQ ID NO: 124

GUUCUUUGUGCCUAUUGCAGU 571

ACCUUUGACUGCAAUAGGCAC 572

SEQ ID NO: 125

GCCUAUUGCAGUCAAAGGUCU 573

AGACCUUUGACUGCAAUAGGC 574

SEQ ID NO: 126

CUAUUGCAGUCAAAGGUCUCA 575

AAUUCGUGAGACCUUUGACUG 576

SEQ ID NO: 127

GUCAAAGGUCUCACGAAUUCC 577

UCUUGAACCUCAUCACUGCAG 578

SEQ ID NO: 128

GCAGUGAUGAGGUUCAAGAAG 579

UUCUUGAACCUCAUCACUGCA 580

SEQ ID NO: 129

CAGUGAUGAGGUUCAAGAAGU 581

ACUUCUUGAACCUCAUCACUG 582

SEQ ID NO: 130

GUGAUGAGGUUCAAGAAGUUU 583

AAACUUCUUGAACCUCAUCAC 584

SEQ ID NO: 131

GAUGAGGUUCAAGAAGUUUUU 585

AGGAAAAACUUCUUGAACCUC 586

SEQ ID NO: 132

GGUUCAAGAAGUUUUUCCUCC 587 UUGUAAUGUCUGGACAUAGAA 588

SEQ ID NO: 133

CUAUGUCCAGACAUUACAAGA 589

AAAGACCAGAGCUUUGCUGGG 590

SEQ ID NO: 134

CAGCAAAGCUCUGGUCUUUGA 591

UCAAAGACCAGAGCUUUGCUG 592

SEQ ID NO: 135

GCAAAGCUCUGGUCUUUGAGG 593

AGAAGCAUGCCCGUUCCUCUC 594

SEQ ID NO: 136

GAGGAACGGGCAUGCUUCUGA 595

AUCUCUAGGCCUGGUCAUCCC 596

SEQ ID NO: 137

GAUGACCAGGCCUAGAGAUGC 597

UGAUCUUGUGCAACUCUGGGC 598

SEQ ID NO: 138

CCAGAGUUGCACAAGAUCAAC 599

UUGAUCUUGUGCAACUCUGGG 600

SEQ ID NO: 139

CAGAGUUGCACAAGAUCAACC 601

ACAUCAUCCCCUUGGACACCA 602

SEQ ID NO: 140

GUGUCCAAGGGGAUGAUGUUA 603

UUACCACUCCCCGUGUUGCCG 604

SEQ ID NO: 141

GCAACACGGGGAGUGGUAAGA 605

ACAACAGGCUGCUCUUACCAC 606

SEQ ID NO: 142

GGUAAGAGCAGCCUGUUGUCA 607

AUGUUCUCCCUGAUGUUCCCG 608

SEQ ID NO: 143

GGAACAUCAGGGAGAACAUCC 609

UCCAAAGGGCAGAAGUUCCAG 610

SEQ ID NO: 144

GGAACUUCUGCCCUUUGGAGA 611

UGUCAUGUCUCCAAAGGGCAG 612

SEQ ID NO: 145

GCCCUUUGGAGACAUGACAGA 613

UCUGUCAUGUCUCCAAAGGGC 614

SEQ ID NO: 146

CCUUUGGAGACAUGACAGAGA 615

AAUGCACUCCUCAAAAAUGUG 616

SEQ ID NO: 147

CAUUUUUGAGGAGUGCAUUAA 617

AAAAUUCUAAGUACUGCAGCU 618

SEQ ID NO: 148

CUGCAGUACUUAGAAUUUUGU 619

ACAAAAUUCUAAGUACUGCAG 620

SEQ ID NO: 149

GCAGUACUUAGAAUUUUGUGG 621

UGAUCUGGCCACAAAAUUCUA 622

SEQ ID NO: 150

GAAUUUUGUGGCCAGAUCAUU 623

UCCAACAAAAUGAUCUGGCCA 624

SEQ ID NO: 151

GCCAGAUCAUUUUGUUGGAAA 625

UUCCAACAAAAUGAUCUGGCC 626

SEQ ID NO: 152

CCAGAUCAUUUUGUUGGAAAA 627

UUUCCAACAAAAUGAUCUGGC 628

SEQ ID NO: 153

CAGAUCAUUUUGUUGGAAAAU 629

AUUUUCCAACAAAAUGAUCUG 630

SEQ ID NO: 154

GAUCAUUUUGUUGGAAAAUGG 631

ACAGAUUUUCCCAUUUUCCAA 632

SEQ ID NO: 155

GGAAAAUGGGAAAAUCUGUGA 633

UCCAUUUUCACAGAUUUUCCC 634

SEQ ID NO: 156

GAAAAUCUGUGAAAAUGGAAC 635 UUAACUCACUGUGAGUUCCAU 636

SEQ ID NO: 157

GGAACUCACAGUGAGUUAAUG 637

AUUAACUCACUGUGAGUUCCA 638

SEQ ID NO: 158

GAACUCACAGUGAGUUAAUGC 639

UGCAUUAACUCACUGUGAGUU 640

SEQ ID NO: 159

CUCACAGUGAGUUAAUGCAGA 641

UCUGCAUUAACUCACUGUGAG 642

SEQ ID NO: 160

CACAGUGAGUUAAUGCAGAAA 643

UUUCUGCAUUAACUCACUGUG 644

SEQ ID NO: 161

CAGUGAGUUAAUGCAGAAAAA 645

UUUUUCUGCAUUAACUCACUG 646

SEQ ID NO: 162

GUGAGUUAAUGCAGAAAAAGG 647

AUAUUUCCCCUUUUUCUGCAU 648

SEQ ID NO: 163

GCAGAAAAAGGGGAAAUAUGC 649

UAAGUUGGGCAUAUUUCCCCU 650

SEQ ID NO: 164

GGGAAAUAUGCCCAACUUAUC 651

AUAAGUUGGGCAUAUUUCCCC 652

SEQ ID NO: 165

GGAAAUAUGCCCAACUUAUCC 653

AUCUUCUGGAUAAGUUGGGCA 654

SEQ ID NO: 166

CCCAACUUAUCCAGAAGAUGC 655

UUCCUUGUGCAUCUUCUGGAU 656

SEQ ID NO: 167

CCAGAAGAUGCACAAGGAAGC 657

UGCUAUCUUUGCUGUGUCCUG 658

SEQ ID NO: 168

GGACACAGCAAAGAUAGCAGA 659

UCUACCUUUGGCUUCUCUGCU 660

SEQ ID NO: 169

CAGAGAAGCCAAAGGUAGAAA 661

ACUUUCUACCUUUGGCUUCUC 662

SEQ ID NO: 170

GAAGCCAAAGGUAGAAAGUCA 663

AGCAUUUCCGUUGAGAGACUC 664

SEQ ID NO: 171

GUCUCUCAACGGAAAUGCUGU 665

ACAGCAUUUCCGUUGAGAGAC 666

SEQ ID NO: 172

CUCUCAACGGAAAUGCUGUGC 667

ACUCAAGGAGCCUUCUUCCAU 668

SEQ ID NO: 173

GGAAGAAGGCUCCUUGAGUUG 669

AACUCAAGGAGCCUUCUUCCA 670

SEQ ID NO: 174

GAAGAAGGCUCCUUGAGUUGG 671

UGCAAGAGACCAUGUAACCUC 672

SEQ ID NO: 175

GGUUACAUGGUCUCUUGCAUA 673

AUGCAAGAGACCAUGUAACCU 674

SEQ ID NO: 176

GUUACAUGGUCUCUUGCAUAA 675

AAUUAUGCAAGAGACCAUGUA 676

SEQ ID NO: 177

CAUGGUCUCUUGCAUAAUUUU 677

AGAAAAUUAUGCAAGAGACCA 678

SEQ ID NO: 178

GUCUCUUGCAUAAUUUUCUUC 679

AAGAAGAAAAUUAUGCAAGAG 680

SEQ ID NO: 179

CUUGCAUAAUUUUCUUCUUCG 681

ACGAAGAAGAAAAUUAUGCAA 682

SEQ ID NO: 180

GCAUAAUUUUCUUCUUCGUGG 683 UUAAGAAGACGAUCAGCACCA 684

SEQ ID NO: 181

GUGCUGAUCGUCUUCUUAACG 685

UCGUUAAGAAGACGAUCAGCA 686

SEQ ID NO: 182

CUGAUCGUCUUCUUAACGAUC 687

UGAAGAUCGUUAAGAAGACGA 688

SEQ ID NO: 183

GUCUUCUUAACGAUCUUCAGC 689

AGGAUUGUCUGCAAUGUUGCC 690

SEQ ID NO: 184

CAACAUUGCAGACAAUCCUCA 691

UUGAGGAUUGUCUGCAAUGUU 692

SEQ ID NO: 185

CAUUGCAGACAAUCCUCAACU 693

ACAGUUGAGGAUUGUCUGCAA 694

SEQ ID NO: 186

GCAGACAAUCCUCAACUGUCC 695

UGGUAGAAGGACAGUUGAGGA 696

SEQ ID NO: 187

CUCAACUGUCCUUCUACCAGC 697

UGACCUUGGUGAAAAUCCCUG 698

SEQ ID NO: 188

GGGAUUUUCACCAAGGUCACG 699

UAAAGAGCUUGUUGUGCAGGG 700

SEQ ID NO: 189

CUGCACAACAAGCUCUUUAAC 701

UGUUAAAGAGCUUGUUGUGCA 702

SEQ ID NO: 190

CACAACAAGCUCUUUAACAAG 703

AACCUUGUUAAAGAGCUUGUU 704

SEQ ID NO: 191

CAAGCUCUUUAACAAGGUUUU 705

UGUCAAAGAAACUCAUGGGGC 706

SEQ ID NO: 192

CCCAUGAGUUUCUUUGACACC 707

UAUUGGGAUGGUGUCAAAGAA 708

SEQ ID NO: 193

CUUUGACACCAUCCCAAUAGG 709

UCAAAAGCCGGCCUAUUGGGA 710

SEQ ID NO: 194

CCAAUAGGCCGGCUUUUGAAC 711

UUCAAAAGCCGGCCUAUUGGG 712

SEQ ID NO: 195

CAAUAGGCCGGCUUUUGAACU 713

AAAAGAUGGGCAAGAGCUGGU 714

SEQ ID NO: 196

CAGCUCUUGCCCAUCUUUUCA 715

UGAAAAGAUGGGCAAGAGCUG 716

SEQ ID NO: 197

GCUCUUGCCCAUCUUUUCAGA 717

UAACAGGAUAUAUGGAGACAG 718

SEQ ID NO: 198

GUCUCCAUAUAUCCUGUUAAU 719

AUUAACAGGAUAUAUGGAGAC 720

SEQ ID NO: 199

CUCCAUAUAUCCUGUUAAUGG 721

UUAUGGCUCCCAUUAACAGGA 722

SEQ ID NO: 200

CUGUUAAUGGGAGCCAUAAUC 723

AUAACCAUGAUUAUGGCUCCC 724

SEQ ID NO: 201

GAGCCAUAAUCAUGGUUAUUU 725

AAAUAACCAUGAUUAUGGCUC 726

SEQ ID NO: 202

GCCAUAAUCAUGGUUAUUUGC 727

AAUGAAGCAAAUAACCAUGAU 728

SEQ ID NO: 203

CAUGGUUAUUUGCUUCAUUUA 729

AUAAAUGAAGCAAAUAACCAU 730

SEQ ID NO: 204

GGUUAUUUGCUUCAUUUAUUA 731 AAUAAAUGAAGCAAAUAACCA 732

SEQ ID NO: 205

GUUAUUUGCUUCAUUUAUUAU 733

AUCAUAUAAUAAAUGAAGCAA 734

SEQ ID NO: 206

GCUUCAUUUAUUAUAUGAUGU 735

AUAGUUCUCCAGUCUCUUGAA 736

SEQ ID NO: 207

CAAGAGACUGGAGAACUAUAG 737

UAAAGGAGACCGGCUAUAGUU 738

SEQ ID NO: 208

CUAUAGCCGGUCUCCUUUAUU 739

AGGAUGUGGGAGAAUAAAGGA 740

SEQ ID NO: 209

CUUUAUUCUCCCACAUCCUCA 741

AGAGAAUUGAGGAUGUGGGAG 742

SEQ ID NO: 210

CCCACAUCCUCAAUUCUCUGC 743

UUUCCAUAGACAUGGAUGGAG 744

SEQ ID NO: 211

CCAUCCAUGUCUAUGGAAAAA 745

UUUUCCAUAGACAUGGAUGGA 746

SEQ ID NO: 212

CAUCCAUGUCUAUGGAAAAAC 747

AGUUUUUCCAUAGACAUGGAU 748

SEQ ID NO: 213

CCAUGUCUAUGGAAAAACUGA 749

UGAAGUCUUCAGUUUUUCCAU 750

SEQ ID NO: 214

GGAAAAACUGAAGACUUCAUC 751

AUGAAGUCUUCAGUUUUUCCA 752

SEQ ID NO: 215

GAAAAACUGAAGACUUCAUCA 753

UAAACUGGCUGAUGAAGUCUU 754

SEQ ID NO: 216

GACUUCAUCAGCCAGUUUAAG 755

AUCAGUCAGCCUCUUAAACUG 756

SEQ ID NO: 217

GUUUAAGAGGCUGACUGAUGC 757

UAUUCUGCGCAUCAGUCAGCC 758

SEQ ID NO: 218

CUGACUGAUGCGCAGAAUAAC 759

AAGAUAGAAACAACAGCAGGU 760

SEQ ID NO: 219

CUGCUGUUGUUUCUAUCUUCC 761

UGGAAGAUAGAAACAACAGCA 762

SEQ ID NO: 220

CUGUUGUUUCUAUCUUCCACA 763

UGUGGAAGAUAGAAACAACAG 764

SEQ ID NO: 221

GUUGUUUCUAUCUUCCACACG 765

AUGAUCUCCAGCCUCAAUGCC 766

SEQ ID NO: 222

CAUUGAGGCUGGAGAUCAUGA 767

UGCCAAAAGCCACGAACAGGG 768

SEQ ID NO: 223

CUGUUCGUGGCUUUUGGCAUU 769

AGGAAAUGCCAAAAGCCACGA 770

SEQ ID NO: 224

GUGGCUUUUGGCAUUUCCUCC 771

UGACUUUAAAGGAGUAGGGGG 772

SEQ ID NO: 225

CCCUACUCCUUUAAAGUCAUG 773

AUGACUUUAAAGGAGUAGGGG 774

SEQ ID NO: 226

CCUACUCCUUUAAAGUCAUGG 775

UGAACUGUGCCUCUGUCUCCA 776

SEQ ID NO: 227

GAGACAGAGGCACAGUUCACG 777

UCUACAGCCGUGAACUGUGCC 778

SEQ ID NO: 228

CACAGUUCACGGCUGUAGAGA 779 UCUCUACAGCCGUGAACUGUG 780

SEQ ID NO: 229

CAGUUCACGGCUGUAGAGAGG 781

UGCAGUAUCCUCUCUACAGCC 782

SEQ ID NO: 230

CUGUAGAGAGGAUACUGCAGU 783

UUCAUGUACUGCAGUAUCCUC 784

SEQ ID NO: 231

GGAUACUGCAGUACAUGAAGA 785

ACAUCUUCAUGUACUGCAGUA 786

SEQ ID NO: 232

CUGCAGUACAUGAAGAUGUGU 787

ACACAUCUUCAUGUACUGCAG 788

SEQ ID NO: 234

GCAGUACAUGAAGAUGUGUGU 789

AACUUGUGCCUUCCAUGUGUA 790

SEQ ID NO: 235

CACAUGGAAGGCACAAGUUGU 791

ACAACUUGUGCCUUCCAUGUG 792

SEQ ID NO: 236

CAUGGAAGGCACAAGUUGUCC 793

AUGAUUUCCCCAUGCUGUGGC 794

SEQ ID NO: 237

CACAGCAUGGGGAAAUCAUAU 795

UCCUGAAAUAUGAUUUCCCCA 796

SEQ ID NO: 238

GGGAAAUCAUAUUUCAGGAUU 797

AUCCUGAAAUAUGAUUUCCCC 798

SEQ ID NO: 239

GGAAAUCAUAUUUCAGGAUUA 799

AAUCCUGAAAUAUGAUUUCCC 800

SEQ ID NO: 240

GAAAUCAUAUUUCAGGAUUAU 801

AUUUCAUGUGAUAAUCCUGAA 802

SEQ ID NO: 241

CAGGAUUAUCACAUGAAAUAC 803

UGUAUUUCAUGUGAUAAUCCU 804

SEQ ID NO: 242

GAUUAUCACAUGAAAUACAGA 805

UGUCUCUGUAUUUCAUGUGAU 806

SEQ ID NO: 243

CACAUGAAAUACAGAGACAAC 807

UGUGUUGUCUCUGUAUUUCAU 808

SEQ ID NO: 244

GAAAUACAGAGACAACACACC 809

AAUGUCCACGCCGUCAAUGAG 810

SEQ ID NO: 245

CAUUGACGGCGUGGACAUUUG 811

AGAGCUUGGACCGCAAGUCCU 812

SEQ ID NO: 246

GACUUGCGGUCCAAGCUCUCA 813

AUCACUGAGAGCUUGGACCGC 814

SEQ ID NO: 247

GGUCCAAGCUCUCAGUGAUCC 815

AUCUUGAGGGAUCACUGAGAG 816

SEQ ID NO: 248

CUCAGUGAUCCCUCAAGAUCC 817

UCUGAUGGUUCCUGAGAGCAG 818

SEQ ID NO: 249

GCUCUCAGGAACCAUCAGAUU 819

AGGUUGAAUCUGAUGGUUCCU 820

SEQ ID NO: 250

GAACCAUCAGAUUCAACCUAG 821

UCUAGGUUGAAUCUGAUGGUU 822

SEQ ID NO: 251

CCAUCAGAUUCAACCUAGAUC 823

AUCUAGGUUGAAUCUGAUGGU 824

SEQ ID NO: 252

CAUCAGAUUCAACCUAGAUCC 825

UCAGUGUGACGGUCAAAGGGA 826

SEQ ID NO: 253

CCUUUGACCGUCACACUGACC 827 AGGAAUGUCCUCUCCAAGGCA 828

SEQ ID NO: 254

CCUUGGAGAGGACAUUCCUGA 829

UUGAGAUGGCCUUGGUCAGGA 830

SEQ ID NO: 255

CUGACCAAGGCCAUCUCAAAG 831

AGCUUUUUGGGGAACUUUGAG 832

SEQ ID NO: 256

CAAAGUUCCCCAAAAAGCUGC 833

UGUAUGCAGCUUUUUGGGGAA 834

SEQ ID NO: 257

CCCCAAAAAGCUGCAUACAGA 835

UCUGUAUGCAGCUUUUUGGGG 836

SEQ ID NO: 258

CCAAAAAGCUGCAUACAGAUG 837

AUCUGUAUGCAGCUUUUUGGG 838

SEQ ID NO: 259

CAAAAAGCUGCAUACAGAUGU 839

AGUUUCCACCGUUUUCCACCA 840

SEQ ID NO: 260

GUGGAAAACGGUGGAAACUUC 841

AGAAGUUUCCACCGUUUUCCA 842

SEQ ID NO: 261

GAAAACGGUGGAAACUUCUCU 843

UUGGAGUUGCGAAGCACAGCC 844

SEQ ID NO: 262

CUGUGCUUCGCAACUCCAAGA 845

UGAUCUUGGAGUUGCGAAGCA 846

SEQ ID NO: 263

CUUCGCAACUCCAAGAUCAUC 847

AGGAUGAUCUUGGAGUUGCGA 848

SEQ ID NO: 264

GCAACUCCAAGAUCAUCCUUA 849

AAGGAUGAUCUUGGAGUUGCG 850

SEQ ID NO: 265

CAACUCCAAGAUCAUCCUUAU 851

UCGAUAAGGAUGAUCUUGGAG 852

SEQ ID NO: 266

CCAAGAUCAUCCUUAUCGAUG 853

AUCGAUAAGGAUGAUCUUGGA 854

SEQ ID NO: 267

CAAGAUCAUCCUUAUCGAUGA 855

UUCAUCGAUAAGGAUGAUCUU 856

SEQ ID NO: 268

GAUCAUCCUUAUCGAUGAAGC 857

UCUGUCUCCAUGUCAAUGGAG 858

SEQ ID NO: 269

CCAUUGACAUGGAGACAGACA 859

UCACAGUUCAGCACAGUGGUG 860

SEQ ID NO: 270

CCACUGUGCUGAACUGUGACC 861

UCCCAUUGCCCAUAACCAGGA 862

SEQ ID NO: 271

CUGGUUAUGGGCAAUGGGAAG 863

UCUACCACCUUCCCAUUGCCC 864

SEQ ID NO: 272

GCAAUGGGAAGGUGGUAGAAU 865

UUCUACCACCUUCCCAUUGCC 866

SEQ ID NO: 273

CAAUGGGAAGGUGGUAGAAUU 867

UCAAAUUCUACCACCUUCCCA 868

SEQ ID NO: 274

GGAAGGUGGUAGAAUUUGAUC 869

AUCUCAGUGAAGAAGUGGCUG 870

SEQ ID NO: 275

GCCACUUCUUCACUGAGAUAA 871

UAUCUCAGUGAAGAAGUGGCU 872

SEQ ID NO: 276

CCACUUCUUCACUGAGAUAAG 873

UUAUCUCAGUGAAGAAGUGGC 874

SEQ ID NO: 277

CACUUCUUCACUGAGAUAAGG 875 UCUCCUUAUCUCAGUGAAGAA 876

SEQ ID NO: 278

CUUCACUGAGAUAAGGAGAUG 877

ACAUCUCCUUAUCUCAGUGAA 878

SEQ ID NO: 279

CACUGAGAUAAGGAGAUGUGG 879

AUGAAGUCUCCACAUCUCCUU 880

SEQ ID NO: 280

GGAGAUGUGGAGACUUCAUGG 881

UCCAUGAAGUCUCCACAUCUC 882

SEQ ID NO: 281

GAUGUGGAGACUUCAUGGAGG 883

AGACUGUGGGCCUCGAAGCUG 884

SEQ ID NO: 282

GCUUCGAGGCCCACAGUCUGC 885

AAGAAGGUCGCAGACUGUGGG 886

SEQ ID NO: 283

CACAGUCUGCGACCUUCUUGU 887

AUCUCCAAACAAGAAGGUCGC 888

SEQ ID NO: 284

GACCUUCUUGUUUGGAGAUGA 889

UCAUCUCCAAACAAGAAGGUC 890

SEQ ID NO: 285

CCUUCUUGUUUGGAGAUGAGA 891

AGGAGAAGUUCUCAUCUCCAA 892

SEQ ID NO: 286

GGAGAUGAGAACUUCUCCUGG 893

AUUUACCCCUGCUUCCAGGAG 894

SEQ ID NO: 287

CCUGGAAGCAGGGGUAAAUGU 895

UACAUUUACCCCUGCUUCCAG 896

SEQ ID NO: 289

GGAAGCAGGGGUAAAUGUAGG 897

UUUCCAUCCAGCAAUCCCCAC 898

SEQ ID NO: 290

GGGGAUUGCUGGAUGGAAACC 899

UAUUCCAGGGUUUCCAUCCAG 900

SEQ ID NO: 291

GGAUGGAAACCCUGGAAUAGG 901

UAGCCUAUUCCAGGGUUUCCA 902

SEQ ID NO: 292

GAAACCCUGGAAUAGGCUACU 903

UCAAGUAGCCUAUUCCAGGGU 904

SEQ ID NO: 293

CCUGGAAUAGGCUACUUGAUG 905

AUCAAGUAGCCUAUUCCAGGG 906

SEQ ID NO: 294

CUGGAAUAGGCUACUUGAUGG 907

UGGUUCUGGGGUUCUAAGGUC 908

SEQ ID NO: 295

CCUUAGAACCCCAGAACCAUC 909

AUGGUUCUGGGGUUCUAAGGU 910

SEQ ID NO: 296

CUUAGAACCCCAGAACCAUCU 911

UGUCUUAGAUGGUUCUGGGGU 912

SEQ ID NO: 297

CCCAGAACCAUCUAAGACAUG 913

AUGUCUUAGAUGGUUCUGGGG 914

SEQ ID NO: 298

CCAGAACCAUCUAAGACAUGG 915

AAUCCCAUGUCUUAGAUGGUU 916

SEQ ID NO: 299

CCAUCUAAGACAUGGGAUUCA 917

ACUGAAUCCCAUGUCUUAGAU 918

SEQ ID NO: 300

CUAAGACAUGGGAUUCAGUGA 919

AUGAUCACUGAAUCCCAUGUC 920

SEQ ID NO: 301

CAUGGGAUUCAGUGAUCAUGU 921

ACCACAUGAUCACUGAAUCCC 922

SEQ ID NO: 302

GAUUCAGUGAUCAUGUGGUUC 923 AAAGGAGAACCACAUGAUCAC 924

SEQ ID NO: 303

GAUCAUGUGGUUCUCCUUUUA 925

UUAAAAGGAGAACCACAUGAU 926

SEQ ID NO: 304

CAUGUGGUUCUCCUUUUAACU 927

AAGUUAAAAGGAGAACCACAU 928

SEQ ID NO: 305

GUGGUUCUCCUUUUAACUUAC 929

UGUAAGUUAAAAGGAGAACCA 930

SEQ ID NO: 306

GUUCUCCUUUUAACUUACAUG 931

UCAGCAUGUAAGUUAAAAGGA 932

SEQ ID NO: 307

CUUUUAACUUACAUGCUGAAU 933

AAAUUAUUCAGCAUGUAAGUU 934

SEQ ID NO: 308

CUUACAUGCUGAAUAAUUUUA 935

UAUAAAAUUAUUCAGCAUGUA 936

SEQ ID NO: 309

CAUGCUGAAUAAUUUUAUAAU 937

UAUUAUAAAAUUAUUCAGCAU 938

SEQ ID NO: 310

GCUGAAUAAUUUUAUAAUAAG 939

UUAUUAUAAAAUUAUUCAGCA 940

SEQ ID NO: 311

CUGAAUAAUUUUAUAAUAAGG 941

AAAACUAUAAGCUUUUACCUU 942

SEQ ID NO: 312

GGUAAAAGCUUAUAGUUUUCU 943

AGAUCAGAAAACUAUAAGCUU 944

SEQ ID NO: 313

GCUUAUAGUUUUCUGAUCUGU 945

AACACUUCUAACACAGAUCAG 946

SEQ ID NO: 314

GAUCUGUGUUAGAAGUGUUGC 947

UUUGCAACACUUCUAACACAG 948

SEQ ID NO: 315

GUGUUAGAAGUGUUGCAAAUG 949

ACAGCAUUUGCAACACUUCUA 950

SEQ ID NO: 316

GAAGUGUUGCAAAUGCUGUAC 951

UCAGUACAGCAUUUGCAACAC 952

SEQ ID NO: 317

GUUGCAAAUGCUGUACUGACU 953

AAGUCAGUACAGCAUUUGCAA 954

SEQ ID NO: 318

GCAAAUGCUGUACUGACUUUG 955

AAAGUCAGUACAGCAUUUGCA 956

SEQ ID NO: 319

CAAAUGCUGUACUGACUUUGU 957

UUUACAAAGUCAGUACAGCAU 958

SEQ ID NO: 320

GCUGUACUGACUUUGUAAAAU 959

UUUUACAAAGUCAGUACAGCA 960

SEQ ID NO: 321

CUGUACUGACUUUGUAAAAUA 961

UAUUUUACAAAGUCAGUACAG 962

SEQ ID NO: 322

GUACUGACUUUGUAAAAUAUA 963

UUAUAUUUUACAAAGUCAGUA 964

SEQ ID NO: 323

CUGACUUUGUAAAAUAUAAAA 965

UUUUAUAUUUUACAAAGUCAG 966

SEQ ID NO: 324

GACUUUGUAAAAUAUAAAACU 967

AGUUUUAUAUUUUACAAAGUC 968

SEQ ID NO: 325

CUUUGUAAAAUAUAAAACUAA 969

It is noted that the particular sequences listed in this table do not include any 3 ' nucleotide overhangs. However, this is not intended to preclude the use of suitable 3 ' nucleotide overhangs. The use of any suitable number and variety of 3' nucleotide overhangs is contemplated. Thus, any suitable 3 ' overhangs can be used with the guide strands and the passenger strands listed in Table 2.

As described above, in some examples, one or more siRNA inhibitors listed in Table 2 can be used to inhibit expression of the ABCCll gene. In one example, the

ABCCl l inhibitor can include a sequence listed in Table 2, or a compliment thereof. Such sequence can further include any required delivery components to create a deliverable construct, including relevant promotors, viral vectors, etc. In some examples, one or more siRNA inhibitors having a guide strand listed in Table 2, or a guide strand at least 90% or 95% homologous thereto, can be used to inhibit expression of the ABCCll gene. In some examples, two or more, three or more, four or more, five or more, or ten or more siRNA inhibitors having a guide strand listed in Table 2, or a guide strand at least 90%) or 95%o homologous thereto, can be used to inhibit expression of the ABCCll gene. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 326, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 328, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 330, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 332, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 334, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 336, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 338, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 340, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 342, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 344, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 346, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 348, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 350, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 352, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 354, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 356, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID

NO: 358, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 360, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 362, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 364, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 366, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 368, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 370, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 372, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 374, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 376, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 378, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 380, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 382, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 384, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 386, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 388, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 390, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 392, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ

ID NO: 394, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 396, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 398, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 400, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 402, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 404, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 406, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 408, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 410, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 412, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 414, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 416, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 418, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 420, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 422, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 424, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 426, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 428, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID

NO: 430, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 432, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 434, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 436, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 438, or a sequence that is at least 90% or 95%o homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 440, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 442, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 444, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 446, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 448, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 450, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 452, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 454, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 456, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 458, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 460, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 462, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 464, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID

NO: 466, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 468, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 470, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 472, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 474, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 476, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 478, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 480, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 482, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 484, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 486, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 488, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 490, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 492, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 494, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 496, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 498, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 500, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 502, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 504, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 506, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 508, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 510, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 512, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 514, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 516, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 518, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 520, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 522, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 524, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 526, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 528, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 530, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 532, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 534, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

536, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 538, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 540, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 542, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 544, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 546, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 548, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 550, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 552, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 554, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 556, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 558, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 560, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 562, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 564, or a sequence that is at least 90% or 95%o homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 566, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 568, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 570, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

572, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 574, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 576, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 578, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 580, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 582, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 584, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 586, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 588, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 590, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 592, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 594, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 596, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 598, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 600, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 602, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 604, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 606, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

608, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 610, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 612, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 614, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 616, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 618, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 620, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 622, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 624, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 626, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 628, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 630, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 632, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 634, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 636, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 638, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 640, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 642, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

644, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 646, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 648, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 650, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 652, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 654, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 656, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 658, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 660, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 662, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 664, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 666, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 668, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 670, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 672, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 674, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 676, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 678, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

680, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 682, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 684, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 686, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 688, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 690, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 692, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 694, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 696, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 698, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 700, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 702, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 704, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 706, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 708, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 710, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 712, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 714, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO:

716, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 718, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 720, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 722, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 724, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 726, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 728, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 730, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 732, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 734, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 736, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 738, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 740, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 742, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 744, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 746, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 748, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 750, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 752, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 754, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 756, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 758, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 760, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 762, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 764, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 766, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 768, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 770, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 772, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 774, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 776, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 778, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 780, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 782, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 784, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 786, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 788, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 790, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 792, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 794, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 796, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 798, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 800, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 802, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 804, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 806, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 808, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 810, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 812, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 814, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 816, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 818, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 820, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 822, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 824, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 826, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 828, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 830, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 832, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 834, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 836, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 838, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 840, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 842, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 844, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 846, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 848, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 850, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 852, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 854, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 856, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 858, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 860, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 862, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 864, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 866, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 868, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 870, or a sequence that is at least 90% or 95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 872, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 874, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 876, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 878, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ

ID NO: 880, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 882, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 884, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 886, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 888, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 890, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 892, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 894, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 896, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 898, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 900, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 902, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 904, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 906, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 908, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 910, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 912, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 914, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID

NO: 916, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 918, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 920, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 922, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 924, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 926, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 928, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 930, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 932, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 934, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 936, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 938, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 940, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 942, or a sequence that is at least 90% or

95%) homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 944, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 946, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 948, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 950, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ

ID NO: 952, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 954, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 956, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 958, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 960, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 962, or a sequence that is at least 90%) or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 964, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 966, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 968, or a sequence that is at least 90% or 95% homologous thereto. Alternatively to or in combination with one or more of the guide strands listed in Table 2, one or more of the following guide strands, or a strand 90% or 95% homologous thereto, can also be employed in the present methods and/or compositions to inhibit expression of the ABCC11 gene: GUUUCAGGACUUAUUUAUA (SEQ ID NO: 970), CCUACUUCAUUAUUGGAUA (SEQ ID NO: 971), GUCCUGUCCUUAAUGGUGA

(SEQ ID NO: 972), and CAAAGAUCCUGGAAUAUUC (SEQ ID NO: 973). In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 970, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 971, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 972, or a sequence that is at least 90% or 95% homologous thereto. In some examples, the one or more siRNA inhibitors can include a guide strand having a sequence of SEQ ID NO: 973, or a sequence that is at least 90% or 95%) homologous thereto.

It is also noted that one or more of the guide strands listed above, or a portion thereof, can also be used as an ASO. In some examples, one or more of the guide strands listed above, or the portion thereof, can be modified with phosphorothioate linkages in place of phosphodiester bonds to increase the stability of the single stranded RNA for use as an ASO. In some examples, one or more of the guide strands listed above, or the portion thereof, can be modified to include a 2'-0-methyl group, 2'-fluoro group, 2'-0- methoxyethyl group, the like, or a combination thereof to increase the stability of the single stranded RNA for use as an ASO. In some examples, one or more of the guide strands, or the portion thereof, can be modified with locked nucleic acid (LNA), which contains a methylene bridge between the 2' and 4' position of the ribose to increase the stability of the single stranded RNA for use as an ASO. Any suitable combination of these modifications, or other similar, related, or suitable modification, can be employed with one or more of the guide strands listed above, or the portion thereof, to prepare a suitable ASO for use in inhibiting expression of the ABCC11 gene. In some examples, a 15-19 nucleotide portion of one or more of the guide strands listed above can be employed as an ASO to inhibit expression of the ABCC11 gene. It is also noted that any RNA inhibitor described herein can include the modifications listed above with respect to ASOs, or similar modifications, to increase the stability thereof. In some examples, the RNA sequences can include modifications to either the phosphate-sugar backbone or the base. For example, the phosphodiester linkages of the RNA can be modified to include at least one of a nitrogen, sulfur, or heteroatom. Likewise, in some examples, bases can be modified to block the activity of adenosine deaminase. It is further noted that the RNA sequence can be prepared by any suitable method. In some examples, the RNA sequence can be produced enzymatically. In other examples, the RNA sequence can be produced by partial or total organic synthesis. In some examples, additional moieties can be included to facilitate self- delivery of the RNA sequence, such a lipids, sugars (e.g. N-acetylgalactosamine (GalNAc)), ligands, peptides, cholesterol, the like, or combinations thereof to facilitate cellular uptake of the RNA inhibitor. Thus, in some examples, the RNA inhibitor can include self-delivery modifications so as to not require the addition of transfection reagents and aids.

The RNA sequences of the present invention can be administered in a variety of forms. For example, in some cases, RNA sequences can be administered as hybridized double stranded complementary RNA (dsRNA), as single stranded RNA (ssRNA), as a single hairpin molecule of RNA (shRNA), as ribozymes, as DNA antisense (AS), as nucleic acid mimics such as peptide nucleic acids or mopholinos, or in any other suitable form. Whether administered as dsRNA, ssRNA, shRNA, or AS, there are a variety of mechanisms by which the RNA/DNA sequences of the present invention can be delivered to a subject.

Suitable delivery mechanisms include but are not limited to injections, including intradermal injection using single needles and needle arrays, topical formulations, such as lotions, creams, gels, ointments, jellies (such as petroleum jelly), adhesives, pastes, liquids, soaps, shampoos, transdermal patches, films, electrophoresis, sonoporation, iontophoresis, nanoparticles, the like, or combinations thereof. In one aspect, the specific carrier utilized in the production of a formation may be selected because of its positive impact on skin. For example, in some cases, carriers that moisturize, hydrate, or otherwise benefit the skin can be used. In yet other examples, carriers that absorb moisture from the skin can be beneficial. This can help eliminate an environment in which odor-producing bacterial thrive. Thus, in some examples, the carrier can include a water-absorbing component (i.e. dessicant).

In further detail, in some examples, a therapeutically effective amount of an RNA inhibitor can be administered via injection, such as intramuscular injection, intravenous injection, subcutaneous injection, intrathecal injection, intradermal injection, transdermal injection or the like. In such examples, the pharmaceutically acceptable carrier can include a variety of components, such as water, a solubilizing or dispersing agent, a tonicity agent, a pH adjuster or buffering agent, a preservative, a chelating agent, a bulking agent, the like, or a combination thereof. In some examples, an injectable therapeutic composition can include a solubilizing or dispersing agent. Non-limiting examples of solubilizing or dispersing agents can include polyoxyethylene sorbitan monooleates, lecithin, polyoxyethylene polyoxypropylene co-polymers, propylene glycol, glycerin, ethanol, polyethylene glycols, sorbitol, dimethylacetamide, polyethoxylated castor oils, n-lactamide, cyclodextrins, caboxymethyl cellulose, acacia, gelatin, methyl cellulose, polyvinyl pyrrolidone, the like, or combinations thereof.

In some examples, an injectable therapeutic composition can include a tonicity agent. Non-limiting examples of tonicity agents can include sodium chloride, potassium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, dextrose, glycerin, propylene glycol, ethanol, trehalose, phosphate-buffered saline (PBS), Dulbecco's PBS,

Alsever's solution, Tris-buffered saline (TBS), water, balanced salt solutions (BSS), such as Hank's BSS, Earle's BSS, Grey's BSS, Puck's BSS, Simm's BSS, Tyrode's BSS, and BSS Plus, the like, or combinations thereof. The tonicity agent can be used to provide an appropriate tonicity of the therapeutic composition. In one aspect, the tonicity of the therapeutic composition can be from about 250 to about 350 milliosmoles/liter

(mOsm/L). In another aspect, the tonicity of the therapeutic composition can be from about 277 to about 310 mOsm/L.

In some examples, an injectable therapeutic composition can include a pH adjuster or buffering agent. Non-limiting examples of pH adjusters or buffering agents can include a number of acids, bases, and combinations thereof, such as hydrochloric acid, phosphoric acid, citric acid, sodium hydroxide, potassium hydroxide, calcium hydroxide, acetate buffers, citrate buffers, tartrate buffers, phosphate buffers, triethanolamine (TRIS) buffers, the like, or combinations thereof. Typically, the pH of the therapeutic composition can be from about 5 to about 9, or from about 6 to about 8.

In some examples, an injectable therapeutic composition can include a preservative. Non-limiting examples of preservatives can include ascorbic acid, acetylcysteine, bisulfite, metabi sulfite, monothioglycerol, phenol, meta-cresol, benzyl alcohol, methyl paraben, propyl paraben, butyl paraben, benzalkonium chloride, benzethonium chloride, butylated hydroxyl toluene, myristyl gamma-picolimium chloride, 2-phenoxyethanol, phenyl mercuric nitrate, chlorobutanol, thimerosal, tocopherols, the like, or combinations thereof.

In some examples, an injectable therapeutic composition can include a chelating agent. Non-limiting examples of chelating agents can include ethylenediaminetetra acetic acid, calcium, calcium disodium, versetamide, calteridol, diethylenetriaminepenta acetic acid, the like, or combinations thereof. In some examples, an injectable therapeutic composition can include a bulking agent. Non-limiting examples of bulking agents can include sucrose, lactose, trehalose, mannitol, sorbitol, glucose, rafinose, glycine, histidine, polyvinyl pyrrolidone, the like, or combinations thereof.

In one example, a method of treating osmidrosis in a subject is disclosed. The method can comprise administering to the subject a therapeutically effective amount of an

ABCC11 inhibitor, wherein the ABCC11 inhibitor is delivered to the subject via injection.

In some examples, a therapeutically effective amount of the RNA inhibitor can be administered via a microneedle array. Such microneedle arrays can include a base portion and a plurality of microneedles attached to, or projecting from the surface of the base portion. In some examples, the base portion can be a polymer layer. The microneedles can be applied to a skin surface of a subject in a manner sufficient to embed the microneedles into the skin surface. In some embodiments, the base portion of the microneedle array can then be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base portion can be removed from the skin surface. In such examples, the microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject. In other embodiments, the base portion and the microneedles can remain connected.

The microneedles of the microneedle array can have any suitable length. In some examples, the microneedles can have a length from about 1 μιη to about 10,000 μιη. In yet other examples, the microneedles can have a length from about 50 μιη to about 1,000 μιη. In still other examples, the microneedles can have a length from about 75 μιη to about 500 μιη.

The microneedle array can have any suitable number of microneedles, depending on the size and distribution of the microneedles. In some examples, the microneedle array can have from about 1 microneedle to about 25,000,000 microneedles. In some examples, the microneedle array can have from about 10 microneedles to about 200 microneedles. In yet other examples, the microneedle array can have from about 50 microneedles to about 500 microneedles. In yet other examples, the microneedle array can have from about 100 microneedles to about 1000 microneedles. In yet other examples, the microneedle array can have from about 500 microneedles to about 50,000 microneedles. In still additional examples, the microneedle array can have from about 10,000 microneedles to about 10,000,000 microneedles.

The microneedle arrays can have a variety of distributions of microneedles. For example, in some cases, the microneedles can be spaced on the base portion at a density of from about 1 microneedle per square centimeter (cm ² ) to about 2500 microneedles per cm ² . In other examples, the microneedles can be spaced on the base portion at a density of from about 10 microneedles per cm ² to about 100 microneedles per cm ² . In other examples, the microneedles can be spaced on the base portion at a density of from about 50 microneedles per cm ² to about 200 microneedles per cm ² . In yet other examples, the microneedles can be spaced on the base portion at a density of from about 100 microneedles per cm ² to about 1000 microneedles per cm ² . In still other examples, the microneedles can be spaced on the base portion at a density of from about 500 microneedles per cm ² to about 2500 microneedles per cm ² .

The microneedle array can be fabricated to simultaneously apply needles to a range of skin surface areas. For example, the microneedle arrays can be fabricated as a continuous sheet, which can optionally be sub-divided into smaller unit doses. In some examples, the microneedle array unit dose can be fabricated to have a surface area or to cover a skin surface area from 1 mm ² to 20 cm ² or from 10 cm ² to 80 cm ² . In yet other examples, the microneedle array unit dose can be fabricated to have a surface area or to cover a skin surface area from 50 cm ² to 150 cm ² , or from 100 cm ² to 1 m ² . In one specific embodiment, the unit dose can have a surface area or cover a skin surface area from 1 cm ² to 350 cm ² . Unit dose size can be preselected to be appropriate for treating the skin surface of a particular body part, such as the palm of the hand, the sole of the foot, or the front or back torso, for example. Further, the flexible sheets of microneedles can be cut into shapes convenient for application to a selected body part. Thus, the microneedle array can have the shape of a circle, an oval, a triangle, a square, a rectangle, a trapezoid, a rhombus, a crescent, a polygonal shape, or any other suitable shape for a particular application. Alternatively, a preselected shape can be dispensed as the base layer and needles subsequently produced from that base layer of a preselected shape.

In some examples, the microneedles of the microneedle arrays can be made of bioabsorbable/biodegradable materials and, in some further examples, can also include materials that can hydrate to form an intradermal and/or subcutaneous depot upon administration. Non-limiting examples of bioabsorbable/biodegradable materials that can be used include polyvinyl alcohol, polyvinylpyrrolidone, carbomers, polyacrylic acid, polyoxyethylene/polyoxypropylene copolymers, other copolymers, albumins, casein, zein, collagen, other proteins, glucose, sucrose, maltose, trehalose, amylose, dextrose, fructose, mannose, galactose, other sugars, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, other sugar alcohols, chondroitin and/or other glycosaminoglycans, inulin, starches, acacia gum, agar, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, alginates, carrageenan, cassia gums, cellulose gums, chitin, chitosan, curdlan, gelatin, dextran, fibrin, fulcelleran, gellan gum, ghatti gum, guar gum, tragacanth, karaya gum, locust bean gum, pectin, starch, tara gum, xanthan gum, and other polysaccharides, and functionalized derivatives of any of the above, copolymers thereof, or mixtures thereof. The bioabsorbable/biodegradable materials are generally only limited by the ability to create a viscous solution in a solvent that can volatilize during formation of the fiber-like needle structure, and/or the property of drying to form a glassy or non-crystalline solid. In one example, a method of treating osmidrosis in a targeted region of a subject is disclosed. The method can comprise administering to the subject a therapeutically effective amount of an ABCCl l inhibitor, wherein the ABCCl l inhibitor is delivered to the subject via a microneedle array. In one aspect, a topical formulation containing a therapeutically effective amount of an ABCCl l inhibitor can be used to treat the symptoms of osmidrosis at a targeted localized region or area of subject's skin by direct application thereto. Further, the topical formulations can be formulated for local and/or systemic delivery of one or more components of the therapeutic composition. Where the therapeutic composition is formulated for topical or transdermal administration, the pharmaceutically acceptable carrier can include a variety of components suitable for forming a suspension, dispersion, lotion, cream, ointment, gel, foam, patch, powder, paste, sponge, shampoo, jellies (such as petroleum jelly), adhesives, pastes, liquids, soaps, the like, or a combination thereof. Non-limiting examples can include a solubilizer, an emulsifier, a dispersant, a thickener, an emollient, a pH adjuster, a tonicity agent, a preservative, an adhesive, a penetration enhancer, the like, or a combination thereof.

Non-limiting examples of solubilizers and/or emulsifiers can include water, ethanol, propylene glycol, ethylene glycol, glycerin, polyethylene glycol, banzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol- 9, octoxynol, polyoxyethylene polyoxypropylene co-polymers, polyoxyl castor oils, polyoxyl hydrogenated castor oils, polyoxyl oleyl ethers, polyoxyl cetylstearyl ethers, polyoxyl stearates, polysorbates, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol, the like, or combinations thereof. In some examples, the solubilizer can also include a hydrocarbon or fatty substance, such as petrolatum, microcrystalline wax, paraffin wax, mineral oil, ceresi, coconut oil, bees wax, olive oil, lanolin, peanut oil, spermaceti wax, sesame oil, almond oil, hydrogenated castor oils, cotton seed oil, soybean oil, corn oil, hydrogenated sulfated castor oils, cetyl alcohol, stearyl alcohol, oleyl alcohol, lauryl alcohol, myristyl alcohol, stearic acid, oleic acid, palmitic acid, lauraic acid, ethyl oleate, isopropyl myristicate, the like, or combinations thereof. In some examples, the solubilizer can include a silicon, such as polydimethylsiloxanes, methicones, dimethylpropylsiloxanes, methyl phenyl polysiloxanes, steryl esters of dimethyl polysiloxanes, ethoxylated dimethicones, ethoxylated methicones, the like, or combinations thereof.

In some additional examples, the therapeutic composition can include a dispersant and/or thickening agent, such as polyacrylic acids (e.g. Carbopols, for example), gelatin, pectin, tragacanth, methyl cellulose, hydroxylethylcellulose, hydroxypropylcellulose,

HPMC, CMC, alginate, starch, polyvinyl alcohol, polyvinyl pyrrolidone, co-polymers of polyoxyethylene and polyoxypropylene, polyethylene glycol, the like, or combinations thereof.

In some examples, the therapeutic composition can include an emollient, such as aloe vera, lanolin, urea, petrolatum, shea butter, cocoa butter, mineral oil, paraffin, beeswax, squalene, jojoba oil, coconut oil, sesame oil, almond oil, cetyl alcohol, stearyl alcohol, olive oil, oleic acid, triethylhexanoin, glycerol, sorbitol, propylene glycol, cyclomethicone, dimethicone, the like, or combinations thereof. A wide range of emollient additives are known in the art and any of these may be included in the present compositions. The emollient component may provide multiple advantages, which include but are not limited to improving the cosmetic feel and appearance of the formulation during application and after drying. Generally, inclusion of emollient materials is understood by those versed in the art to suppress evaporation rate and to reduce the chemical potential of the drug-solvent system in regard to percutaneous absorption. In one embodiment, the emollient can be present in the formulation in an amount from 0.1 wt% to 10 wt%. In another embodiment, the emollient can be present in the formulation in an amount from 0.1 wt% to 5 wt%. In another embodiment, the emollient can be present in the formulation in an amount from 0.5 wt% to 3 wt%.

In some examples, the topical or transdermal composition can include an adhesive, such as acrylic adhesives, polyisobutylene adhesives, silicon adhesives, hydrogel adhesives, the like, or combinations thereof.

In some examples, the topical or transdermal composition can include a penetration enhancer, such as ethanol, propylene glycol, oleic acid and other fatty acids, azone, terpenes, terpenoids, bile acids, isopropyl myristate and other fatty esters, dimethyl sulphoxides, N-methyl-2-pyrrolidone and other pyrrolidones, the like, or combinations thereof. The pH adjusters, tonicity agents, and preservatives can also be included in the topical or transdermal therapeutic composition, such as those pH adjusters and buffering agents, tonicity agents, and preservative agents listed above, or any other suitable pH adjusters, buffering agent, tonicity agent, or preservative for a particular formulation and/or use thereof. In some examples, the topical or transdermal therapeutic composition can also include fumed silica, mica, talc, titanium dioxide, kaolin, aluminum glycinate, ethylenediaminetetraacetic acid, fragrances, colorants, other components as described above, the like, or combinations thereof.

In some specific examples, the topical or transdermal delivery system can be in the form of aqueous lotions or creams. These topical or transdermal delivery systems can be such that following application to a skin surface, the skin surface is dry, or substantially dry, to the touch within about 1 minute to about 5 minutes. In one embodiment, the following application of the transdermal delivery system to a skin surface, the skin surface is dry, or substantially dry, to the touch within about 1 minute to about 2 minutes. In another embodiment, following application to a skin surface, the skin surface is dry, or substantially dry, to the touch in less than about 1 minute. In one embodiment, the formulation of the present invention can be substantially free of triglycerides, waxes, or liquid surfactants that, following application to a skin surface and being allowed to dry, are left behind on the skin surface (i.e. leave a residue). Following drying, the topical or transdermal delivery system of the present disclosure typically does not leave a residue on the skin surface. This is advantageous in that the risk of transfer of the substances, particularly the siRNA, from the skin is significantly reduced as compared to other non-aqueous formulations (e.g. ointments). Further, by reducing superficial residue on the skin surface, the presence of materials that might solubilize siRNA locally at the skin surface without assisting their transport onto or into the skin is reduced, which tendency might otherwise act to compromise the efficacy of the composition. For instance, if a triglyceride residue remained at the surface of the skin while the other components evaporated or absorbed into the skin, the residual triglyceride would be likely to dissolve a fraction of the siRNA active ingredient, which would therefore be less available to be delivered by the percutaneous absorbing portions of the formulation, as topically applied triglycerides are not understood to penetrate significantly into the skin. The compositional make-up of the topical or transdermal delivery systems disclosed herein can be such that they have a low yield stress value (e.g. dynes/cm ² ), which allows it to be readily applied to sensitive skin areas without requiring substantial pressure for rubbing or spreading. Nonetheless, the yield stress value of the compositions is still high enough to provide for convenient, localized, and non-messy application. This is particularly advantageous in that many conditions that can be treated with formulations of the present invention often result in tender or sensitive skin. Accordingly, the transdermal delivery systems described herein can provide for better patient compliance.

In some specific examples, the topical delivery vehicle can comprise a polymer having surfactant properties, a polymer having thickening properties, a solvent for solubilizing the ABCC11 inhibitor, a glycol, a Ci ₀ -C ₂ o fatty acid, a base, and water.

Polymers having surfactant properties (surfactant polymers) can include a wide array of surfactant or emulsifying polymers that are known in the art. Non-limiting examples of polymers having surfactant or emulsifying properties include, but are not limited to hydrophobically modified polyacrylic acid commercially under the tradename

Pemulen™ TR-I and TR-2 by Lubrizol Corp., water-soluble or water-swellable copolymers based on acrylamidoalkyl sulfonic acid and cyclic N-vinylcarboxamides commercially available under the tradename Aristoflex® AVC by Clariant Corporation; water-soluble or water-swellable copolymers based on acrylamidoalkyl sulfonic acid and hydrophobically modified methacrylic acid commercially available under the tradename

Aristoflex® HMB by Clariant Corporation and a homopolymer of acrylamidoalkyl sulfonic acid commercially available under the tradename Granthix APP by Grant Industries, Inc. Another class of notable polymeric emulsifier includes hydrophobically- modified, crosslinked, anionic acrylic copolymers, including random polymers, but may also exist in other forms such as block, star, graft, and the like. In one embodiment, the hydrophobically modified, crosslinked, anionic acrylic copolymer may be synthesized from at least one acidic monomer and at least one hydrophobic ethylenically unsaturated monomer. Examples of suitable acidic monomers include those ethylenically unsaturated acid monomers that may be neutralized by a base. Examples of suitable hydrophobic ethylenically unsaturated monomers include those that contain a hydrophobic chain having a carbon chain length of at least about 3 carbon atoms. Other materials that may be suitable polymeric surfactants can include ethylene oxide/ propylene oxide block copolymers, sold under the trade name PLURONIC ^® , available from BASF Corporation of Parsippany, NJ., modified cellulose polymers such as those modified cellulose polymers described by the trade name KLUCEL ^® , available from Hercules Corporation of Wilmington, DE. Particularly notable embodiments of the invention are compositions that include hydrophobically modified polyacrylic acid, acrylamidoalkyl sulfonic acid, cyclic N- vinylcarboxamides, acrylamidoalkyl sulfonic acid, hydrophobically modified methacrylic acid, a homopolymer of acrylamidoalkyl sulfonic acid, or combinations thereof as polymeric emulsifiers; and monomelic anionic surfactants, monomeric amphoteric surfactants, or combinations thereof as foaming agents. More particularly notable embodiments of the invention are compositions that include hydrophobically modified polyacrylic acid; water-soluble or water-swellable copolymers based on acrylamidoalkyl sulfonic acid, cyclic N-vinylcarboxamides; water- soluble or water-swellable copolymers based on acrylamidoalkyl sulfonic acid, hydrophobically modified methacrylic acid; a homopolymer of acrylamidoalkyl sulfonic acid, or combinations thereof as polymeric emulsifiers, and include a betaine as the foaming surfactant. Especially notable embodiments of the invention are compositions that include copolymers based on acrylamidoalkylsulfonic acids and cyclic N- vinylcarboxamides and/or linear N- vinylcarboxamides (e.g., Aristoflex® AVC and Aristoflex® HMB from Clariant Corporation) as polymeric emulsifiers and a betaine as foaming surfactant.

Polymers having surfactant properties can enhance the ability of a formulation to support highly loaded emulsions of low polarity oils, and it has been discovered that it is in some circumstances possible to extend this capability to form emulsions of an intermediate polarity material as well. In some embodiments, the surfactant polymer can comprise about 0.01 wt% to about 3 wt%. In one embodiment, the surfactant polymer can comprise about 0.1 wt% to about 1.0 wt% of the formulations of the present invention. In one embodiment, the surfactant polymer can comprise about 0.1 wt% to about 0.5 wt% of the total formulation. In another embodiment, the surfactant polymer can comprise about 0.15 wt% to about 0.3 wt% of the total formulation.

The formulations of the present invention also can include a polymer having thickening properties (thickening polymer). In one embodiment, the polymer having thickening properties can be a hydrophobically modified cross-linked acrylate copolymer (Carbopol ^® Ultrez 20). Other polymers having similar properties may also be used. Non- limiting examples of polymers having thickening properties can include PEG- 150 distearate, PEG-7 glyceryl cocoate, PEG-200 hydrogenated glyceryl palmitate, PEG- 120 methyl glucose dioleate, carboxymethylene polymer, carboxyvinyl polymer, acrylates,

C10-C30 alkyl acrylate crosspolymers, and combinations thereof. In some embodiments, the polymer having thickening properties can comprise about 0.1 wt% to about 3 wt%. In another embodiment, polymers having thickening properties can be present in amounts of 0.4 wt% to about 1.0 wt% of the total composition. In one embodiment, the polymer having thickening properties comprises about 0.5 wt% to about 0.75 wt% of the total composition. The thickening polymer can be mixed with the surfactant polymer and water as a component of an aqueous phase.

In some embodiments, the formulations of the present invention can also include a base or buffer system, which is present in the formulation to neutralize and/or activate the thickening polymer in order to facilitate the formation of a composition having the desirable rheological qualities. Any base or buffer system known in the art and suitable for use in a skin contact application can be used. In one embodiment, the base can include triethanolamine, such as solutions of 10% triethanolamine (TEA), tetrasodium ethylenediaminetetraacetic acid (EDTA), alkali metal hydroxides like sodium hydroxide (NaOH), salts of weak acids such as ammonium lactate, sodium citrate, sodium ascorbate, or mixtures thereof. The base component also provides utility in that the pH of the overall composition may be adjusted to a range favorable for minimizing irritation of the skin due to pH effects. In some embodiments formulations of the present invention can also include an acid or the acid component of a buffer system, and any acid known in the art and appropriate for human skin contact may be used. Examples of acids useful in the present formulation and commonly used to adjust pH of topical formulations include but are not limited to: citric acid, lactic acid, ascorbic acid, and hydrochloric acid, and combinations of these and similar acids. Generally the pH of the formulations of the present invention can be between about 5.0 and about 7.0.

The formulations of the present invention can also include a glycol and/or glycol ether. Non-limiting examples of glycols and glycol ethers can be selected from butylene glycol, propylene glycol, diethylene glycol (Transcutol), triethylene glycol, ethylene glycol monomethyl ether, or other glycols and glycol ethers, and combinations thereof. The formulations can also include a Ci ₀ -C ₂ o fatty acid. Non-limiting examples of C ₁₀ - C ₂ o fatty acid can include oleic acid, arachidonic acid, linoleic acid, linolenic acid, or other fatty acids or combinations of fatty acids, and preferably unsaturated cis conformation fatty acids. Without being bound to any particular interpretation, such conformations are understood to disrupt superficial packing of the structured lipids of the stratum corneum, thereby promoting fluidization of these lipids and thus enhancing the diffusion of the drug and/or solvent into the skin, and are believed to play this role in the present formulation. In one embodiment, the Cio-C ₂₀ fatty acid can be oleic acid.

In one example, a method of treating osmidrosis in a targeted region of a subject is disclosed. The method can comprise topically administering to the subject a therapeutically effective amount of an ABCC l l inhibitor, wherein the ABCCl l inhibitor is delivered to the subject via a topical or transdermal delivery vehicle.

The effectiveness of osmidrosis inhibition can depend on the particular RNA inhibitor as well as the amount of inhibiting RNA administered to the subject. Other biologically-related factors may also be important in determining the effectiveness of the inhibitors. In some examples, therapeutically effective amounts of RNA sequences can be from about 0.01 mg per squared cm of body surface area per day to about 50 mg per squared cm of body surface area per day. In other examples, therapeutically effective amounts of RNA sequences can be from about 0.05 mg per squared cm of body surface area per day to about 20 mg per squared cm of body surface area per day. In yet other examples, therapeutically effective amounts of RNA sequences can be from about 0.1 mg per squared cm of body surface area per day to about 10 mg per squared cm of body surface area per day.

Various factors can affect an appropriate amount of an ABCC l l inhibitor to ameliorate osmidrosis symptoms in a subject. Such factors can include the specific

ABCCl l inhibitor or inhibitors being used, type or extent of odor-producing condition experienced by the subject, the age and weight of the subject, as well as various other physical and genetic factors, other medications being used to treat the patient, and many other factors known by those skilled in the relevant arts. As a result, there are a range of therapeutically effective amounts that can be used for treating the osmidrosis of a subject, which can depend on the above listed factors and others. In one aspect, a therapeutically effective amount can be an osmidrosis-reducing amount. In another aspect, a therapeutically effective amount can be an odor-removal or odor-reducing amount.

In some examples, a therapeutically effective amount can include an amount from about 0.01 mg to about 100 mg per day. In another aspect, a therapeutically effective amount can include an amount from about 0.1 mg per day to about 50 mg per day. In another aspect, a therapeutically effective amount can include an amount from about 0.2 mg to about 20 mg per day. In yet a further aspect, a therapeutically effective amount can include an amount from about 0.2 mg to about 1 mg per day.

In one embodiment, the amount of ABCCl l inhibitor that is therapeutically effective may be sufficient to provide a reduction of osmidrosis severity; delay of onset of odor following stimuli; accelerate removal of odor following stimuli; etc. When applied to a target region that also includes a condition or disease that causes the osmidrosis symptoms, the amount of ABCCl l inhibitor can also be sufficient to provide prolonged reduction of osmidrosis. As previously mentioned, the therapeutically effective amount of an ABCCl l inhibitor present pharmaceutically acceptable carrier can vary depending on the particular ABCCl l inhibitor being used, the mode of administration being employed, the severity of the condition, the particular subject being treated, etc. In one embodiment, the delivery system can include from about 0.0001 wt% to about 20 wt% of an ABCCl l inhibitor. In another embodiment, the delivery system can include about 0.0005 wt% to about 10 wt% of the formulation. In another embodiment, the ABCCl l inhibitor can comprise about 0.001 wt% to about 5 wt% of the formulation. In another embodiment, the ABCCl l inhibitor can comprise about 0.005 to about 1 wt% of the formulation. In still a further embodiment, the ABCCl l inhibitor can comprise about 0.01 wt% to about 0.5 wt% of the formulation. In one embodiment, the ABCCl 1 inhibitor can comprise about 0.05 wt% to about 0.1 wt% of the formulation. In some specific examples, the ABCCl l inhibitor can comprise about 0.0001 wt% to about 0.001 wt%, about 0.001 wt% to about 0.01 wt%, or from about 0.005 wt% to about 0.05 wt%. In one example, the ABCCl 1 inhibitor can be an siRNA. In some examples, a therapeutically effective amount of the inhibitor or therapeutic agent can be an amount sufficient to inhibit expression of an ABCCll gene in a target cell of the subject to an osmidrosis-reducing level. In some examples, an osmidrosis-reducing level of expression can be at least 30% lower than baseline. In additional examples, an osmidrosis-reducing level of expression can be at least 40% lower than baseline. In yet additional examples, an osmidrosis-reducing level of expression can be at least 50% lower than baseline. In still additional examples, an osmidrosis-reducing level of expression can be at least 60% lower than baseline. In further examples, an osmidrosis-reducing level of expression can be at least 65%, 67%, or 69% lower than baseline.

As previously mentioned, in some examples, the RNA inhibitors can be modified to enable passive uptake of the inhibitor. In other words, in some examples, the inhibitor can be modified for self-delivery (e.g. Accell siRNAs, or the like) without the need for electroporation, viral-mediated delivery of the inhibitor, liposomic/polymeric carriers, or the like. In yet other examples, cationic liposomes or polymeric carriers can be employed to facilitate transfection of the inhibitor into a target cell. In still other examples, electroporation or the like can be employed to facilitate transfection into a target cell. In other examples, the RNA inhibitor can be delivered via viral-mediated delivery. Where this is the case, any suitable viral vector can be employed, such as lentivirus, retrovirus, adenovirus, adeno-associated virus, the like, or a combination thereof.

In some examples, an additional therapeutic agent can be included in the composition and/or administered contemporaneously with the therapeutic agent. Non- limiting examples can include antimicrobials (e.g. antib acted als, antifungals, antivirals, antiparasitics, etc.) or agents that reduce overall sweating such as antiperspirants and botulinum toxin or other toxins.

In some specific examples, the composition can include an antibacterial agent. Non-limiting examples of antibacterial agents can include triclosan, triclocarban, chloroxylenol, dicloxacillin, cephalexin, cefuroxime, clindamycin, bacitracin, polymixin B, neomycin, gentamicin, mupirocin, the like, or combinations thereof. Alternatively, one or more antibacterial agents, such as those listed above, can be administered separately from the compositions described herein, but as part of a method of treating osmidrosis. For example, in some cases, it can be desirable to administer the composition locally, whereas it can be desirable to administer the antibacterial agent systemically, or vice versa. In yet other examples, the composition can include an antiperspirant. Non- limiting examples of antiperspirants can include any one of aluminum chlorohydrate, aluminum chloride, aluminum hydroxide, aluminum chlorohydrex polyethylene glycol, aluminum chlorohydrex propylene glycol, aluminum di chlorohydrate, aluminum di chlorohydrex polyethylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrate, aluminum sesquichlorohydrate polyethylene glycol, aluminum sesquichlorohydrate propylene glycol, aluminum-zirconium octachl orohy drate, ai um in urn -zirconium octachl orohy drex gly ci ne, al mi num-zi rconi urn pentachloro hy drate, aluminum-zirconium pentachlorohydrex glycine, aluminum-zirconium tetrachiorohy drate, aiuminuni-zirconium tetrachl orohy drex glycine, aluminum-zirconium trichlorohydrate, aluminum-zirconium tri chlorohydrex glycine, potassium aluminum sulfate, aluminum undecyienoyl collagen amino acid, sodium aluminum lactate, aluminum sulfate, sodium aluminum chl orohy droxy lactate, aluminum bromohydrate, aluminum chlorohy droxy a] 1 an toinate, zinc chloride, z nc suifocarboSate, zinc sulfate, zirconium chlorohydrate, the like, or any suitable combinations thereof in some other examples, the composition can further include a toxin. Non- limiting examples of toxins can include any one of botulinum toxin, cyanotoxins, such as anatoxin-a, lyngbyatoxin-a, aplysiatoxins, and other toxins produced by cyanobacteria; dinotoxins, such as saxitoxins and gonyautoxins, and other toxins produced by dinoflagellates; necrotoxins, causing necrosis or cell death, such as toxins found in the brown recluse spider, venom of the rattlesnake and other vipers, pore forming toxins of necrotizing fasciitis bacteria; neurotoxins, including toxins that disrupt ion channel conductance, comprising tetrodotoxin, chlorotoxin, conotoxin, botulinum toxin, tetanus toxin, anatoxin, bungarotoxin, carambotoxin, curare poisons, and those found in the venom of the black widow spider, jellyfish, elapid snakes, venomous fish, mollusks, and amphibians, coral and some algae; myotoxins found in snake and lizard venoms; cytotoxins, such as ricin, apitoxin, and mycotoxins, including aflatoxins, ochratoxins, citrinin, ergot toxins, patulin, fumonisins, trichothecenes, zearalenone, beauvercin, enniatins, butenolide, equisetin, fusarins, batroxobins, batrachotoxins, cobrotoxins, crotamines, didemnins, deltorphins, exendins, gephyrotoxin, hannalgesins, histrionicotoxins, opitoxins, phycotoxins, scorpion toxins (such as scorpion β-toxins, etc.), spider toxins (such as co-agatoxins, psalmotoxins, etc.), the like, or any suitable combination thereof. The present methods and compositions can be illustrated by a number of nonexclusive embodiments as follows:

A method of treating an osmidrosis condition in a subject can include

administering a therapeutic agent in an amount that is effective to inhibit expression of an ABCC11 gene in a target cell of the subject to an osmidrosis-reducing level.

In some examples, the osmidrosis condition includes axillary osmidrosis, pectoral osmidrosis, genital osmidrosis, or a combination thereof. In some examples, the osmidrosis condition includes axillary oxmidrosis.

In some examples, the osmidrosis condition includes pectoral osmidrosis.

In some examples, the osmidrosis condition includes genital osmidrosis.

In some examples, administration is performed locally at a situs of the condition.

In some examples, the situs includes one or more of the axillary region, the chest region, and the genital region.

In some examples, the situs includes the axillary region.

In some examples, the situs includes the chest/pectoral region. In some examples, the situs includes the genital region.

In some examples, administration is performed via injection, microneedle array, topical administration, transdermal administration, or a combination thereof. In some examples, administration is performed via injection.

In some examples, administration is performed via microneedle array. In some examples, administration is performed via topical administration.

In some examples, administration is performed via transdermal administration.

In some examples, the therapeutic agent is configured to inhibit expression of the ABCC11 gene in the target cell via gene therapy.

In some examples, the therapeutic agent is a member selected from the group consisting of a CRISPR/Cas9 system, a therapeutic polynucleotide including a rsl7822931 single-nucleotide polymorphism (SNP), and a combination thereof.

In some examples, the therapeutic agent is a member selected from the group consisting of small interfering RNAs (siRNAs), micro RNAs (miRNAs), morpholinos, antisense oligonucleotides (ASOs), peptide nucleic acids, small molecule inhibitors, and combinations thereof.

In some examples, the therapeutic agent is administered in an amount of from about 0.01 mg to about 100 mg per dose.

In some examples, the therapeutic agent includes a self-delivery modification to facilitate uptake by the target cell.

In some examples, the self-delivery modification includes one or more of lipids, cholesterol, natural ligands, peptides, and chemical modifications.

In some examples, the therapeutic agent is an siRNA.

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 13 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973). In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 15 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 17 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 19 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 13 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 15 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 17 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 19 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA has a sequence that is at least 90% homologous to SEQ ID NO: 970, SEQ ID NO: 971, SEQ ID NO: 972, or SEQ ID NO: 973.

In some examples, the siRNA has a sequence that is at least 95% homologous to SEQ ID NO: 970, SEQ ID NO: 971, SEQ ID NO: 972, or SEQ ID NO: 973. In some examples, the therapeutic agent is configured to target one or more gene sequences individually selected from SEQ ID NOs: 2 through 325 to inhibit expression of the ABCC11 gene.

In some examples, the target cell is an apocrine cell.

In some examples, the target cell is an axillary apocrine cell.

In some examples, the target cell is a pectoral apocrine cell. In some examples, the target cell is a genital apocrine cell.

In some examples, the osmodrosis-reducing level of expression is at least 30% lower than baseline. In some examples, the osmodrosis-reducing level of expression is at least 40% lower than baseline.

In some examples, the osmodrosis-reducing level of expression is at least 50% lower than baseline.

In some examples, the osmodrosis-reducing level of expression is at least 60% lower than baseline. In some examples, the osmodrosis-reducing level of expression is at least 65% lower than baseline.

In some examples, a therapeutic composition for treating an osmidrosis condition in a subject can include a therapeutically effective amount of an ABCC11 gene-inhibiting agent and a pharmaceutically acceptable carrier.

In some examples, the amount of therapeutic agent is an amount sufficient to reduce expression of the ABCC11 gene to a level at least 30% below baseline.

In some examples, the amount of therapeutic agent is an amount sufficient to reduce expression of the ABCC11 gene to a level at least 40% below baseline.

In some examples, the amount of therapeutic agent is an amount sufficient to reduce expression of the ABCC11 gene to a level at least 50% below baseline.

In some examples, the amount of therapeutic agent is an amount sufficient to reduce expression of the ABCC11 gene to a level at least 60% below baseline.

In some examples, the amount of therapeutic agent is an amount sufficient to reduce expression of the ABCC11 gene to a level at least 65% below baseline.

In some examples, the therapeutic agent is a member selected from the group consisting of a CRISPR/Cas9 system, a therapeutic polynucleotide including a rsl7822931 single-nucleotide polymorphism (S P), and a combination thereof.

In some examples, the therapeutic agent is a member selected from the group consisting of: small interfering RNAs (siRNAs), micro RNAs (miRNAs), morpholinos, antisense oligonucleotides (ASOs), peptide nucleic acids, small molecule inhibitors, and combinations thereof.

In some examples, the therapeutic agent includes a self-delivery modification to facilitate uptake by the target cell. In some examples, the self-delivery modification includes one or more of a lipid, cholesterol, a natural ligand, a peptide, and a chemical modification.

In some examples, the therapeutic agent includes an siRNA.

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 13 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 15 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 17 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 90%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 19 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 13 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 15 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 17 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA includes a sequence that is at least 95%

homologous to any one of SEQ ID NOs: 326 through 973, or a segment thereof having at least 19 consecutive nucleotides of any one of said sequences (i.e. SEQ ID NOs: 326 through 973).

In some examples, the siRNA has a sequence that is at least 90% homologous to SEQ ID NO: 970, SEQ ID NO: 971, SEQ ID NO: 972, or SEQ ID NO: 973.

In some examples, the siRNA has a sequence that is at least 95% homologous to SEQ ID NO: 970, SEQ ID NO: 971, SEQ ID NO: 972, or SEQ ID NO: 973. In some examples, the therapeutic agent is present in the composition in an amount from about 0.0001 wt% to about 20 wt%.

In some examples, the pharmaceutically acceptable carrier is formulated for injection.

In some examples, the pharmaceutically acceptable carrier is formulated as a microneedle array.

In some examples, the pharmaceutically acceptable carrier is formulated as a topical or transdermal delivery system.

In some examples, the composition further includes an additional therapeutic agent. In some examples, the additional therapeutic agent is a member selected from the group consisting of: an antimicrobial, an antiperspirant, a toxin, and combinations thereof.

Example

Human HepG2 liver cells (seeded onto 96 well plates at 0.3xl0 ⁵ cells per well from stock cultures from an -80% confluent T75 tissue culture flask (cultured in RPMI supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, pen/strep antibiotics and glutamine as well as IX MEM EAA solution) were transfected (using RNAiMax,

Therm oFisher) with 3 nM, 10 nM, or 30 nM of each of four distinct siRNAs (containing Accell self-delivery and stability modifications proprietary to GE Life Sciences/Dharmacon Division) targeting ABCC11. After a 48-hour incubation period in a 37 °C C0 ₂ incubator, cells were harvested, RNA extracted and subjected to RT-qPCR using TaqMan primer/probe sets (ABCC 11 probe cat# Hs01090768_ml ABCC11 FAM and hGAPDH probe cat# Hs99999905_ml GAPDH FAM). The results are illustrated in FIG. 1. The resulting data were normalized to GAPDH and demonstrate that ABCC 11 #16 siRNA treatment results in 69% inhibition from baseline levels. Further, each of the siRNAs employed in this study resulted in at least 34% inhibition from baseline levels at an amount of 30 nM.

It should be understood that the above-described methods are only illustrative of some embodiments of the present invention. Numerous modifications and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of the present invention and the appended claims are intended to cover such modifications and arrangements. Thus, while the present invention has been described above with particularity and detail in connection with what is presently deemed to be the most practical and preferred embodiments of the invention, it will be apparent to those of ordinary skill in the art that variations including, may be made without departing from the principles and concepts set forth herein.